{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "fe1ef227",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "%matplotlib inline\n",
    "import matplotlib.pyplot as plt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "583fed06",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Generic Name</th>\n",
       "      <th>Trade Name</th>\n",
       "      <th>Date Designated</th>\n",
       "      <th>Orphan Designation</th>\n",
       "      <th>Orphan Designation Status</th>\n",
       "      <th>FDA Orphan Approval Status</th>\n",
       "      <th>Approved Labeled Indication</th>\n",
       "      <th>Marketing Approval Date</th>\n",
       "      <th>Exclusivity End Date</th>\n",
       "      <th>Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)</th>\n",
       "      <th>Sponsor Company</th>\n",
       "      <th>Sponsor Address 1</th>\n",
       "      <th>Sponsor Address 2</th>\n",
       "      <th>Sponsor City</th>\n",
       "      <th>Sponsor State</th>\n",
       "      <th>Sponsor Zip</th>\n",
       "      <th>Sponsor Country</th>\n",
       "      <th>CF Grid Key</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>bosentan</td>\n",
       "      <td>Tracleer</td>\n",
       "      <td>10/06/00</td>\n",
       "      <td>Treatment of pulmonary arterial hypertension</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Treatment of pulmonary arterial hypertension.</td>\n",
       "      <td>11/20/2001</td>\n",
       "      <td>11/20/2008</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Actelion Pharmaceuticals Ltd</td>\n",
       "      <td>1840 Gateway Drive</td>\n",
       "      <td>Suite 300</td>\n",
       "      <td>Cherry Hill</td>\n",
       "      <td>New Jersey</td>\n",
       "      <td>8002</td>\n",
       "      <td>United States</td>\n",
       "      <td>134200.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>bosentan</td>\n",
       "      <td>Tracleer</td>\n",
       "      <td>10/06/00</td>\n",
       "      <td>Treatment of pulmonary arterial hypertension</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Treatment of pulmonary arterial hypertension (...</td>\n",
       "      <td>9/05/17</td>\n",
       "      <td>9/05/24</td>\n",
       "      <td>Treatment of pulmonary arterial hypertension (...</td>\n",
       "      <td>Actelion Pharmaceuticals Ltd</td>\n",
       "      <td>1840 Gateway Drive</td>\n",
       "      <td>Suite 300</td>\n",
       "      <td>Cherry Hill</td>\n",
       "      <td>New Jersey</td>\n",
       "      <td>8002</td>\n",
       "      <td>United States</td>\n",
       "      <td>134200.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>(tisagenlecleucel) Autologous T Cells transduc...</td>\n",
       "      <td>Kymriah (tisagenlecleucel)</td>\n",
       "      <td>01/31/2014</td>\n",
       "      <td>For the treatment of Acute Lymphoblastic Leukemia</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Treatment of patients up to 25 years of age wi...</td>\n",
       "      <td>08/30/2017</td>\n",
       "      <td>08/30/2024</td>\n",
       "      <td>Treatment of patients up to 25 years of age wi...</td>\n",
       "      <td>Novartis Pharmaceuticals Corporation</td>\n",
       "      <td>One Health Plaza,</td>\n",
       "      <td>Bldg 315 - Room 3650B</td>\n",
       "      <td>East Hanover</td>\n",
       "      <td>New Jersey</td>\n",
       "      <td>7936</td>\n",
       "      <td>United States</td>\n",
       "      <td>415113.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>5-aminolevulinic acid</td>\n",
       "      <td>Gleolan</td>\n",
       "      <td>01/15/2013</td>\n",
       "      <td>Visualization of malignant tissue during surge...</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Optical imaging agent indicated in patients wi...</td>\n",
       "      <td>6/06/17</td>\n",
       "      <td>6/06/24</td>\n",
       "      <td>Optical imaging agent indicated in patients wi...</td>\n",
       "      <td>NX Development Corporation</td>\n",
       "      <td>1827 South Bayshore Lane</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Miami</td>\n",
       "      <td>Florida</td>\n",
       "      <td>33133</td>\n",
       "      <td>United States</td>\n",
       "      <td>387312.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>abatacept</td>\n",
       "      <td>Orencia</td>\n",
       "      <td>12/26/2017</td>\n",
       "      <td>Prevention of graft versus host disease</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>NaN</td>\n",
       "      <td>prophylaxis of acute graft versus host disease...</td>\n",
       "      <td>12/15/2021</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Bristol-Myers Squibb Co.</td>\n",
       "      <td>P. O. Box 5326</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Princeton</td>\n",
       "      <td>New Jersey</td>\n",
       "      <td>8543</td>\n",
       "      <td>United States</td>\n",
       "      <td>614117.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        Generic Name  \\\n",
       "0                                           bosentan   \n",
       "1                                           bosentan   \n",
       "2  (tisagenlecleucel) Autologous T Cells transduc...   \n",
       "3                              5-aminolevulinic acid   \n",
       "4                                          abatacept   \n",
       "\n",
       "                   Trade Name Date Designated  \\\n",
       "0                    Tracleer        10/06/00   \n",
       "1                    Tracleer        10/06/00   \n",
       "2  Kymriah (tisagenlecleucel)      01/31/2014   \n",
       "3                     Gleolan      01/15/2013   \n",
       "4                     Orencia      12/26/2017   \n",
       "\n",
       "                                  Orphan Designation  \\\n",
       "0       Treatment of pulmonary arterial hypertension   \n",
       "1       Treatment of pulmonary arterial hypertension   \n",
       "2  For the treatment of Acute Lymphoblastic Leukemia   \n",
       "3  Visualization of malignant tissue during surge...   \n",
       "4            Prevention of graft versus host disease   \n",
       "\n",
       "  Orphan Designation Status  FDA Orphan Approval Status  \\\n",
       "0       Designated/Approved                         NaN   \n",
       "1       Designated/Approved                         NaN   \n",
       "2       Designated/Approved                         NaN   \n",
       "3       Designated/Approved                         NaN   \n",
       "4       Designated/Approved                         NaN   \n",
       "\n",
       "                         Approved Labeled Indication Marketing Approval Date  \\\n",
       "0      Treatment of pulmonary arterial hypertension.              11/20/2001   \n",
       "1  Treatment of pulmonary arterial hypertension (...                 9/05/17   \n",
       "2  Treatment of patients up to 25 years of age wi...              08/30/2017   \n",
       "3  Optical imaging agent indicated in patients wi...                 6/06/17   \n",
       "4  prophylaxis of acute graft versus host disease...              12/15/2021   \n",
       "\n",
       "  Exclusivity End Date  \\\n",
       "0           11/20/2008   \n",
       "1              9/05/24   \n",
       "2           08/30/2024   \n",
       "3              6/06/24   \n",
       "4                  NaN   \n",
       "\n",
       "  Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)  \\\n",
       "0                                                NaN                                           \n",
       "1  Treatment of pulmonary arterial hypertension (...                                           \n",
       "2  Treatment of patients up to 25 years of age wi...                                           \n",
       "3  Optical imaging agent indicated in patients wi...                                           \n",
       "4                                                NaN                                           \n",
       "\n",
       "                        Sponsor Company         Sponsor Address 1  \\\n",
       "0          Actelion Pharmaceuticals Ltd        1840 Gateway Drive   \n",
       "1          Actelion Pharmaceuticals Ltd        1840 Gateway Drive   \n",
       "2  Novartis Pharmaceuticals Corporation         One Health Plaza,   \n",
       "3            NX Development Corporation  1827 South Bayshore Lane   \n",
       "4              Bristol-Myers Squibb Co.            P. O. Box 5326   \n",
       "\n",
       "       Sponsor Address 2  Sponsor City Sponsor State Sponsor Zip  \\\n",
       "0              Suite 300   Cherry Hill    New Jersey        8002   \n",
       "1              Suite 300   Cherry Hill    New Jersey        8002   \n",
       "2  Bldg 315 - Room 3650B  East Hanover    New Jersey        7936   \n",
       "3                    NaN         Miami       Florida       33133   \n",
       "4                    NaN     Princeton    New Jersey        8543   \n",
       "\n",
       "  Sponsor Country  CF Grid Key  \n",
       "0   United States     134200.0  \n",
       "1   United States     134200.0  \n",
       "2   United States     415113.0  \n",
       "3   United States     387312.0  \n",
       "4   United States     614117.0  "
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Import data from .csv file\n",
    "df = pd.read_csv('/Users/jenniferlin/Rare_diseases_approved.csv')\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "8d323639",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Generic Name</th>\n",
       "      <th>Trade Name</th>\n",
       "      <th>Date Designated</th>\n",
       "      <th>Orphan Designation</th>\n",
       "      <th>Orphan Designation Status</th>\n",
       "      <th>FDA Orphan Approval Status</th>\n",
       "      <th>Approved Labeled Indication</th>\n",
       "      <th>Marketing Approval Date</th>\n",
       "      <th>Exclusivity End Date</th>\n",
       "      <th>Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)</th>\n",
       "      <th>Sponsor Company</th>\n",
       "      <th>Sponsor Address 1</th>\n",
       "      <th>Sponsor Address 2</th>\n",
       "      <th>Sponsor City</th>\n",
       "      <th>Sponsor State</th>\n",
       "      <th>Sponsor Zip</th>\n",
       "      <th>Sponsor Country</th>\n",
       "      <th>CF Grid Key</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Generic Name  Trade Name  Date Designated  Orphan Designation  \\\n",
       "0         False       False            False               False   \n",
       "1         False       False            False               False   \n",
       "2         False       False            False               False   \n",
       "3         False       False            False               False   \n",
       "4         False       False            False               False   \n",
       "\n",
       "   Orphan Designation Status  FDA Orphan Approval Status  \\\n",
       "0                      False                        True   \n",
       "1                      False                        True   \n",
       "2                      False                        True   \n",
       "3                      False                        True   \n",
       "4                      False                        True   \n",
       "\n",
       "   Approved Labeled Indication  Marketing Approval Date  Exclusivity End Date  \\\n",
       "0                        False                    False                 False   \n",
       "1                        False                    False                 False   \n",
       "2                        False                    False                 False   \n",
       "3                        False                    False                 False   \n",
       "4                        False                    False                  True   \n",
       "\n",
       "   Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)  \\\n",
       "0                                               True                                            \n",
       "1                                              False                                            \n",
       "2                                              False                                            \n",
       "3                                              False                                            \n",
       "4                                               True                                            \n",
       "\n",
       "   Sponsor Company  Sponsor Address 1  Sponsor Address 2  Sponsor City  \\\n",
       "0            False              False              False         False   \n",
       "1            False              False              False         False   \n",
       "2            False              False              False         False   \n",
       "3            False              False               True         False   \n",
       "4            False              False               True         False   \n",
       "\n",
       "   Sponsor State  Sponsor Zip  Sponsor Country  CF Grid Key  \n",
       "0          False        False            False        False  \n",
       "1          False        False            False        False  \n",
       "2          False        False            False        False  \n",
       "3          False        False            False        False  \n",
       "4          False        False            False        False  "
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Check for any missing data in dataframe\n",
    "missing_data = df.isnull()\n",
    "missing_data.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "1d6ea905",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Generic Name\n",
      "False    1058\n",
      "Name: Generic Name, dtype: int64\n",
      "\n",
      "Trade Name\n",
      "False    1013\n",
      "True       45\n",
      "Name: Trade Name, dtype: int64\n",
      "\n",
      "Date Designated\n",
      "False    1057\n",
      "True        1\n",
      "Name: Date Designated, dtype: int64\n",
      "\n",
      "Orphan Designation\n",
      "False    1057\n",
      "True        1\n",
      "Name: Orphan Designation, dtype: int64\n",
      "\n",
      "Orphan Designation Status\n",
      "False    1057\n",
      "True        1\n",
      "Name: Orphan Designation Status, dtype: int64\n",
      "\n",
      "FDA Orphan Approval Status\n",
      "True    1058\n",
      "Name: FDA Orphan Approval Status, dtype: int64\n",
      "\n",
      "Approved Labeled Indication\n",
      "False    1000\n",
      "True       58\n",
      "Name: Approved Labeled Indication, dtype: int64\n",
      "\n",
      "Marketing Approval Date\n",
      "False    1057\n",
      "True        1\n",
      "Name: Marketing Approval Date, dtype: int64\n",
      "\n",
      "Exclusivity End Date\n",
      "False    961\n",
      "True      97\n",
      "Name: Exclusivity End Date, dtype: int64\n",
      "\n",
      "Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)\n",
      "False    549\n",
      "True     509\n",
      "Name: Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present), dtype: int64\n",
      "\n",
      "Sponsor Company\n",
      "False    1057\n",
      "True        1\n",
      "Name: Sponsor Company, dtype: int64\n",
      "\n",
      "Sponsor Address 1\n",
      "False    1056\n",
      "True        2\n",
      "Name: Sponsor Address 1, dtype: int64\n",
      "\n",
      "Sponsor Address 2\n",
      "True     720\n",
      "False    338\n",
      "Name: Sponsor Address 2, dtype: int64\n",
      "\n",
      "Sponsor City\n",
      "False    1057\n",
      "True        1\n",
      "Name: Sponsor City, dtype: int64\n",
      "\n",
      "Sponsor State\n",
      "False    984\n",
      "True      74\n",
      "Name: Sponsor State, dtype: int64\n",
      "\n",
      "Sponsor Zip\n",
      "False    984\n",
      "True      74\n",
      "Name: Sponsor Zip, dtype: int64\n",
      "\n",
      "Sponsor Country\n",
      "False    1057\n",
      "True        1\n",
      "Name: Sponsor Country, dtype: int64\n",
      "\n",
      "CF Grid Key\n",
      "False    1057\n",
      "True        1\n",
      "Name: CF Grid Key, dtype: int64\n",
      "\n"
     ]
    }
   ],
   "source": [
    "#Check how many missing values are there in the dataset\n",
    "for column in missing_data.columns.values.tolist():\n",
    "    print(column)\n",
    "    print(missing_data[column].value_counts())\n",
    "    print(\"\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "f5d1c26c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Generic Name                                                                                   object\n",
       "Trade Name                                                                                     object\n",
       "Date Designated                                                                                object\n",
       "Orphan Designation                                                                             object\n",
       "Orphan Designation Status                                                                      object\n",
       "FDA Orphan Approval Status                                                                    float64\n",
       "Approved Labeled Indication                                                                    object\n",
       "Marketing Approval Date                                                                        object\n",
       "Exclusivity End Date                                                                           object\n",
       "Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)     object\n",
       "Sponsor Company                                                                                object\n",
       "Sponsor Address 1                                                                              object\n",
       "Sponsor Address 2                                                                              object\n",
       "Sponsor City                                                                                   object\n",
       "Sponsor State                                                                                  object\n",
       "Sponsor Zip                                                                                    object\n",
       "Sponsor Country                                                                                object\n",
       "CF Grid Key                                                                                   float64\n",
       "dtype: object"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.dtypes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "343e2538",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Generic Name</th>\n",
       "      <th>Trade Name</th>\n",
       "      <th>Date Designated</th>\n",
       "      <th>Orphan Designation</th>\n",
       "      <th>Orphan Designation Status</th>\n",
       "      <th>Approved Labeled Indication</th>\n",
       "      <th>Marketing Approval Date</th>\n",
       "      <th>Exclusivity End Date</th>\n",
       "      <th>Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)</th>\n",
       "      <th>Sponsor Company</th>\n",
       "      <th>Sponsor Address 1</th>\n",
       "      <th>Sponsor City</th>\n",
       "      <th>Sponsor State</th>\n",
       "      <th>Sponsor Zip</th>\n",
       "      <th>Sponsor Country</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>bosentan</td>\n",
       "      <td>Tracleer</td>\n",
       "      <td>10/06/00</td>\n",
       "      <td>Treatment of pulmonary arterial hypertension</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Treatment of pulmonary arterial hypertension.</td>\n",
       "      <td>11/20/2001</td>\n",
       "      <td>11/20/2008</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Actelion Pharmaceuticals Ltd</td>\n",
       "      <td>1840 Gateway Drive</td>\n",
       "      <td>Cherry Hill</td>\n",
       "      <td>New Jersey</td>\n",
       "      <td>8002</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>bosentan</td>\n",
       "      <td>Tracleer</td>\n",
       "      <td>10/06/00</td>\n",
       "      <td>Treatment of pulmonary arterial hypertension</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Treatment of pulmonary arterial hypertension (...</td>\n",
       "      <td>9/05/17</td>\n",
       "      <td>9/05/24</td>\n",
       "      <td>Treatment of pulmonary arterial hypertension (...</td>\n",
       "      <td>Actelion Pharmaceuticals Ltd</td>\n",
       "      <td>1840 Gateway Drive</td>\n",
       "      <td>Cherry Hill</td>\n",
       "      <td>New Jersey</td>\n",
       "      <td>8002</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>(tisagenlecleucel) Autologous T Cells transduc...</td>\n",
       "      <td>Kymriah (tisagenlecleucel)</td>\n",
       "      <td>01/31/2014</td>\n",
       "      <td>For the treatment of Acute Lymphoblastic Leukemia</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Treatment of patients up to 25 years of age wi...</td>\n",
       "      <td>08/30/2017</td>\n",
       "      <td>08/30/2024</td>\n",
       "      <td>Treatment of patients up to 25 years of age wi...</td>\n",
       "      <td>Novartis Pharmaceuticals Corporation</td>\n",
       "      <td>One Health Plaza,</td>\n",
       "      <td>East Hanover</td>\n",
       "      <td>New Jersey</td>\n",
       "      <td>7936</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>5-aminolevulinic acid</td>\n",
       "      <td>Gleolan</td>\n",
       "      <td>01/15/2013</td>\n",
       "      <td>Visualization of malignant tissue during surge...</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Optical imaging agent indicated in patients wi...</td>\n",
       "      <td>6/06/17</td>\n",
       "      <td>6/06/24</td>\n",
       "      <td>Optical imaging agent indicated in patients wi...</td>\n",
       "      <td>NX Development Corporation</td>\n",
       "      <td>1827 South Bayshore Lane</td>\n",
       "      <td>Miami</td>\n",
       "      <td>Florida</td>\n",
       "      <td>33133</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>abatacept</td>\n",
       "      <td>Orencia</td>\n",
       "      <td>12/26/2017</td>\n",
       "      <td>Prevention of graft versus host disease</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>prophylaxis of acute graft versus host disease...</td>\n",
       "      <td>12/15/2021</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Bristol-Myers Squibb Co.</td>\n",
       "      <td>P. O. Box 5326</td>\n",
       "      <td>Princeton</td>\n",
       "      <td>New Jersey</td>\n",
       "      <td>8543</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        Generic Name  \\\n",
       "0                                           bosentan   \n",
       "1                                           bosentan   \n",
       "2  (tisagenlecleucel) Autologous T Cells transduc...   \n",
       "3                              5-aminolevulinic acid   \n",
       "4                                          abatacept   \n",
       "\n",
       "                   Trade Name Date Designated  \\\n",
       "0                    Tracleer        10/06/00   \n",
       "1                    Tracleer        10/06/00   \n",
       "2  Kymriah (tisagenlecleucel)      01/31/2014   \n",
       "3                     Gleolan      01/15/2013   \n",
       "4                     Orencia      12/26/2017   \n",
       "\n",
       "                                  Orphan Designation  \\\n",
       "0       Treatment of pulmonary arterial hypertension   \n",
       "1       Treatment of pulmonary arterial hypertension   \n",
       "2  For the treatment of Acute Lymphoblastic Leukemia   \n",
       "3  Visualization of malignant tissue during surge...   \n",
       "4            Prevention of graft versus host disease   \n",
       "\n",
       "  Orphan Designation Status  \\\n",
       "0       Designated/Approved   \n",
       "1       Designated/Approved   \n",
       "2       Designated/Approved   \n",
       "3       Designated/Approved   \n",
       "4       Designated/Approved   \n",
       "\n",
       "                         Approved Labeled Indication Marketing Approval Date  \\\n",
       "0      Treatment of pulmonary arterial hypertension.              11/20/2001   \n",
       "1  Treatment of pulmonary arterial hypertension (...                 9/05/17   \n",
       "2  Treatment of patients up to 25 years of age wi...              08/30/2017   \n",
       "3  Optical imaging agent indicated in patients wi...                 6/06/17   \n",
       "4  prophylaxis of acute graft versus host disease...              12/15/2021   \n",
       "\n",
       "  Exclusivity End Date  \\\n",
       "0           11/20/2008   \n",
       "1              9/05/24   \n",
       "2           08/30/2024   \n",
       "3              6/06/24   \n",
       "4                  NaN   \n",
       "\n",
       "  Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)  \\\n",
       "0                                                NaN                                           \n",
       "1  Treatment of pulmonary arterial hypertension (...                                           \n",
       "2  Treatment of patients up to 25 years of age wi...                                           \n",
       "3  Optical imaging agent indicated in patients wi...                                           \n",
       "4                                                NaN                                           \n",
       "\n",
       "                        Sponsor Company         Sponsor Address 1  \\\n",
       "0          Actelion Pharmaceuticals Ltd        1840 Gateway Drive   \n",
       "1          Actelion Pharmaceuticals Ltd        1840 Gateway Drive   \n",
       "2  Novartis Pharmaceuticals Corporation         One Health Plaza,   \n",
       "3            NX Development Corporation  1827 South Bayshore Lane   \n",
       "4              Bristol-Myers Squibb Co.            P. O. Box 5326   \n",
       "\n",
       "   Sponsor City Sponsor State Sponsor Zip Sponsor Country  \n",
       "0   Cherry Hill    New Jersey        8002   United States  \n",
       "1   Cherry Hill    New Jersey        8002   United States  \n",
       "2  East Hanover    New Jersey        7936   United States  \n",
       "3         Miami       Florida       33133   United States  \n",
       "4     Princeton    New Jersey        8543   United States  "
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Drop \"CF Grid Key\" column as this was only for FDA office use only\n",
    "df.drop(columns = ['CF Grid Key'], inplace = True)\n",
    "\n",
    "#Drop \"FDA Orphan Approval Status\" column as this column contained missing values only\n",
    "df.drop(['FDA Orphan Approval Status'], axis = 1, inplace = True)\n",
    "\n",
    "#Drop \"Sponsor Address 2\" column (720 missing values in this column & most likely only need city & state info.)\n",
    "df.drop(columns = ['Sponsor Address 2'], inplace = True)\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "e022913c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Orphan Designation</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>Treatment of multiple myeloma</th>\n",
       "      <td>29</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of chronic lymphocytic leukemia</th>\n",
       "      <td>11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of chronic myelogenous leukemia</th>\n",
       "      <td>11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of patients with cystic fibrosis</th>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of pulmonary arterial hypertension</th>\n",
       "      <td>9</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>For the Treatment of Dravet Syndrome</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of human African trypanosomiasis (HAT) or sleeping sickness</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of pediatric Clostridium difficile infection</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of tumor induced hypercalcemia.</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>727 rows × 1 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                    Orphan Designation\n",
       "Treatment of multiple myeloma                                       29\n",
       "Treatment of chronic lymphocytic leukemia                           11\n",
       "Treatment of chronic myelogenous leukemia                           11\n",
       "Treatment of patients with cystic fibrosis                          10\n",
       "Treatment of pulmonary arterial hypertension                         9\n",
       "...                                                                ...\n",
       "For the Treatment of Dravet Syndrome                                 1\n",
       "Treatment of human African trypanosomiasis (HAT...                   1\n",
       "Treatment of pediatric Clostridium difficile in...                   1\n",
       "For use in the mobilization of peripheral blood...                   1\n",
       "Treatment of tumor induced hypercalcemia.                            1\n",
       "\n",
       "[727 rows x 1 columns]"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Count the types of orphan designations (i.e. initial indications of the rare disease drugs)\n",
    "df['Orphan Designation'].value_counts().to_frame()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "0a64c25b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Initial_od_value_counts</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>Treatment of multiple myeloma</th>\n",
       "      <td>29</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of chronic lymphocytic leukemia</th>\n",
       "      <td>11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of chronic myelogenous leukemia</th>\n",
       "      <td>11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of patients with cystic fibrosis</th>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of pulmonary arterial hypertension</th>\n",
       "      <td>9</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>For the Treatment of Dravet Syndrome</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of human African trypanosomiasis (HAT) or sleeping sickness</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of pediatric Clostridium difficile infection</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of tumor induced hypercalcemia.</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>727 rows × 1 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                    Initial_od_value_counts\n",
       "Treatment of multiple myeloma                                            29\n",
       "Treatment of chronic lymphocytic leukemia                                11\n",
       "Treatment of chronic myelogenous leukemia                                11\n",
       "Treatment of patients with cystic fibrosis                               10\n",
       "Treatment of pulmonary arterial hypertension                              9\n",
       "...                                                                     ...\n",
       "For the Treatment of Dravet Syndrome                                      1\n",
       "Treatment of human African trypanosomiasis (HAT...                        1\n",
       "Treatment of pediatric Clostridium difficile in...                        1\n",
       "For use in the mobilization of peripheral blood...                        1\n",
       "Treatment of tumor induced hypercalcemia.                                 1\n",
       "\n",
       "[727 rows x 1 columns]"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Rename column to value_counts for orphan designation\n",
    "Initial_od_counts = df['Orphan Designation'].value_counts().to_frame()\n",
    "Initial_od_counts.rename(columns = {'Orphan Designation': 'Initial_od_value_counts'}, inplace = True)\n",
    "Initial_od_counts"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "84307720",
   "metadata": {},
   "source": [
    "The orphan designation for rare disease drug that had the highest counts between 1983 till present was for the treatment of multiple myeloma"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "1765a1d4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Approved Labeled Indication</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).</th>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.</th>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen</th>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Limitations of Use: Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.</th>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma</th>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>PROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia.</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of hypercalcemia of malignancy.</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>959 rows × 1 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                    Approved Labeled Indication\n",
       "REVLIMID in combination with a rituximab produc...                            3\n",
       "Treatment of patients with Marginal Zone Lympho...                            3\n",
       "Treatment of adult patients with relapsed or re...                            3\n",
       "Treatment of adult patients with large B-cell l...                            3\n",
       "Treatment of adult patients with relapsed or re...                            3\n",
       "...                                                                         ...\n",
       "EMPLICITI is indicated in combination with poma...                            1\n",
       "PROMACTA is indicated in combination with stand...                            1\n",
       "Treatment of patients with severe aplastic anem...                            1\n",
       "Treatment of thrombocytopenia in patients with ...                            1\n",
       "Treatment of hypercalcemia of malignancy.                                     1\n",
       "\n",
       "[959 rows x 1 columns]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Count types of approved labeled indications (i.e. final approved indications of the rare disease drugs)\n",
    "df['Approved Labeled Indication'].value_counts().to_frame()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "b7c0b2f8",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Approved_li_value_counts</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).</th>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.</th>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen</th>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Limitations of Use: Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.</th>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma</th>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>PROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia.</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Treatment of hypercalcemia of malignancy.</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>959 rows × 1 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                    Approved_li_value_counts\n",
       "REVLIMID in combination with a rituximab produc...                         3\n",
       "Treatment of patients with Marginal Zone Lympho...                         3\n",
       "Treatment of adult patients with relapsed or re...                         3\n",
       "Treatment of adult patients with large B-cell l...                         3\n",
       "Treatment of adult patients with relapsed or re...                         3\n",
       "...                                                                      ...\n",
       "EMPLICITI is indicated in combination with poma...                         1\n",
       "PROMACTA is indicated in combination with stand...                         1\n",
       "Treatment of patients with severe aplastic anem...                         1\n",
       "Treatment of thrombocytopenia in patients with ...                         1\n",
       "Treatment of hypercalcemia of malignancy.                                  1\n",
       "\n",
       "[959 rows x 1 columns]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Rename column to value_counts for approved labeled indications\n",
    "Approved_li_counts = df['Approved Labeled Indication'].value_counts().to_frame()\n",
    "Approved_li_counts.rename(columns = {'Approved Labeled Indication': 'Approved_li_value_counts'}, inplace = True)\n",
    "Approved_li_counts"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f45d9369",
   "metadata": {},
   "source": [
    "The highest counts of final approved indication for rare disease drugs spanned across several different clinical indications as shown above - it often ended up with more indication details than the initial orphan designation phase."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "1fa18c2b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Generic Name</th>\n",
       "      <th>Trade Name</th>\n",
       "      <th>Date Designated</th>\n",
       "      <th>Orphan Designation</th>\n",
       "      <th>Orphan Designation Status</th>\n",
       "      <th>Approved Labeled Indication</th>\n",
       "      <th>Marketing Approval Date</th>\n",
       "      <th>Exclusivity End Date</th>\n",
       "      <th>Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)</th>\n",
       "      <th>Sponsor Company</th>\n",
       "      <th>Sponsor Address 1</th>\n",
       "      <th>Sponsor City</th>\n",
       "      <th>Sponsor State</th>\n",
       "      <th>Sponsor Zip</th>\n",
       "      <th>Sponsor Country</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1053</th>\n",
       "      <td>zanubrutinib</td>\n",
       "      <td>Brukinsa</td>\n",
       "      <td>08/24/2020</td>\n",
       "      <td>Treatment of nodal marginal zone lymphoma</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Treatment of adult patients with relapsed or r...</td>\n",
       "      <td>09/14/2021</td>\n",
       "      <td>09/14/2028</td>\n",
       "      <td>Treatment of adult patients with relapsed or r...</td>\n",
       "      <td>BeiGene USA, Inc.</td>\n",
       "      <td>2955 Campus Drive</td>\n",
       "      <td>San Mateo</td>\n",
       "      <td>California</td>\n",
       "      <td>94403</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1054</th>\n",
       "      <td>zidovudine</td>\n",
       "      <td>Retrovir</td>\n",
       "      <td>07/17/1985</td>\n",
       "      <td>Treatment of AIDS</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Management of certain adult patients with symp...</td>\n",
       "      <td>03/19/1987</td>\n",
       "      <td>03/19/1994</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Glaxo Wellcome Inc.</td>\n",
       "      <td>5 Moore Drive</td>\n",
       "      <td>Research Triangle Park</td>\n",
       "      <td>North Carolina</td>\n",
       "      <td>27709</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1055</th>\n",
       "      <td>Zinc acetate</td>\n",
       "      <td>Galzin</td>\n",
       "      <td>11/06/85</td>\n",
       "      <td>Treatment of Wilson's disease.</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>For maintenance treatment of patients with Wil...</td>\n",
       "      <td>01/28/1997</td>\n",
       "      <td>01/28/2004</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Lemmon Company</td>\n",
       "      <td>1510 Delp Drive</td>\n",
       "      <td>Kulpsville</td>\n",
       "      <td>Pennsylvania</td>\n",
       "      <td>19443</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1056</th>\n",
       "      <td>Zoledronate</td>\n",
       "      <td>Zometa, Zabel</td>\n",
       "      <td>08/18/2000</td>\n",
       "      <td>Treatment of tumor induced hypercalcemia.</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Treatment of hypercalcemia of malignancy.</td>\n",
       "      <td>08/20/2001</td>\n",
       "      <td>08/20/2008</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Novartis Pharmaceuticals Corp.</td>\n",
       "      <td>59 Route 10</td>\n",
       "      <td>East Hanover</td>\n",
       "      <td>New Jersey</td>\n",
       "      <td>7936</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1057</th>\n",
       "      <td>Note: Exclusivity Protected Indications are sh...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                           Generic Name     Trade Name  \\\n",
       "1053                                       zanubrutinib       Brukinsa   \n",
       "1054                                         zidovudine       Retrovir   \n",
       "1055                                       Zinc acetate         Galzin   \n",
       "1056                                        Zoledronate  Zometa, Zabel   \n",
       "1057  Note: Exclusivity Protected Indications are sh...            NaN   \n",
       "\n",
       "     Date Designated                         Orphan Designation  \\\n",
       "1053      08/24/2020  Treatment of nodal marginal zone lymphoma   \n",
       "1054      07/17/1985                          Treatment of AIDS   \n",
       "1055        11/06/85             Treatment of Wilson's disease.   \n",
       "1056      08/18/2000  Treatment of tumor induced hypercalcemia.   \n",
       "1057             NaN                                        NaN   \n",
       "\n",
       "     Orphan Designation Status  \\\n",
       "1053       Designated/Approved   \n",
       "1054       Designated/Approved   \n",
       "1055       Designated/Approved   \n",
       "1056       Designated/Approved   \n",
       "1057                       NaN   \n",
       "\n",
       "                            Approved Labeled Indication  \\\n",
       "1053  Treatment of adult patients with relapsed or r...   \n",
       "1054  Management of certain adult patients with symp...   \n",
       "1055  For maintenance treatment of patients with Wil...   \n",
       "1056          Treatment of hypercalcemia of malignancy.   \n",
       "1057                                                NaN   \n",
       "\n",
       "     Marketing Approval Date Exclusivity End Date  \\\n",
       "1053              09/14/2021           09/14/2028   \n",
       "1054              03/19/1987           03/19/1994   \n",
       "1055              01/28/1997           01/28/2004   \n",
       "1056              08/20/2001           08/20/2008   \n",
       "1057                     NaN                  NaN   \n",
       "\n",
       "     Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)  \\\n",
       "1053  Treatment of adult patients with relapsed or r...                                           \n",
       "1054                                                NaN                                           \n",
       "1055                                                NaN                                           \n",
       "1056                                                NaN                                           \n",
       "1057                                                NaN                                           \n",
       "\n",
       "                     Sponsor Company  Sponsor Address 1  \\\n",
       "1053               BeiGene USA, Inc.  2955 Campus Drive   \n",
       "1054             Glaxo Wellcome Inc.      5 Moore Drive   \n",
       "1055                  Lemmon Company    1510 Delp Drive   \n",
       "1056  Novartis Pharmaceuticals Corp.        59 Route 10   \n",
       "1057                             NaN                NaN   \n",
       "\n",
       "                Sponsor City   Sponsor State Sponsor Zip Sponsor Country  \n",
       "1053               San Mateo      California       94403   United States  \n",
       "1054  Research Triangle Park  North Carolina       27709   United States  \n",
       "1055              Kulpsville    Pennsylvania       19443   United States  \n",
       "1056            East Hanover      New Jersey        7936   United States  \n",
       "1057                     NaN             NaN         NaN             NaN  "
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#To observe the last 5 rows of the data\n",
    "df.tail()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "e97a4452",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['bosentan',\n",
       "       '(tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19',\n",
       "       '5-aminolevulinic acid', 'abatacept', 'acalabrutinib',\n",
       "       'acetylcysteine',\n",
       "       'acetylcysteine effervescent tablets for oral solution',\n",
       "       'acyclovir', 'adalimumab', 'afamelanotide', 'afatinib',\n",
       "       'agalsidase beta', 'Albendazole', 'Aldesleukin', 'alectinib',\n",
       "       'alemtuzumab', 'Alglucerase injection', 'alirocumab',\n",
       "       'Alitretinoin',\n",
       "       'allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat',\n",
       "       'allogeneic processed thymus tissue-agdc', 'Allopurinol sodium',\n",
       "       'alpelisib', 'Alpha1-proteinase inhibitor (human)', 'Altretamine',\n",
       "       'Amantadine hydrochloride', 'ambrisentan',\n",
       "       'amifampridine phosphate', 'Amifostine', 'Aminosalicylic acid',\n",
       "       'Amiodarone HCl', 'Amphotericin B lipid complex', 'Anagrelide',\n",
       "       'anakinra', 'ansuvimab-zykl', 'anthrax immune globulin (human)',\n",
       "       'Anthrax Vaccine Adsorbed', 'anti-inhibitor coagulant complex',\n",
       "       'Antihemophilic factor (human)',\n",
       "       'Antihemophilic factor (recombinant)',\n",
       "       'antihemophilic factor (recombinant), Fc fusion protein',\n",
       "       'antihemophilic factor (recombinant), porcine sequence',\n",
       "       'Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized',\n",
       "       'Antithrombin III (human)',\n",
       "       'Antivenin crotaline (pit-viper) equine immune F(ab)2)',\n",
       "       'Antivenin, crotalidae polyvalent immune Fab (ovine)',\n",
       "       'Apomorphine HCl', 'apremilast', 'Aprotinin', 'aripiprazole',\n",
       "       'Arsenic trioxide', 'artemether/lumefantrine', 'artesunate',\n",
       "       'asciminib', 'ascorbic acid', 'Asfotase alfa',\n",
       "       'asparaginase erwinia chrysanthemi (recombinant)-rywn',\n",
       "       'atezolizumab', 'atezolizumab + bevacizumab',\n",
       "       'atoltivimab, maftivimab, and odesivimab-ebgn', 'Atovaquone',\n",
       "       'avacopan', 'avalglucosidase alfa-ngpt', 'avapritinib',\n",
       "       'avatrombopag maleate',\n",
       "       'avelumab (Recombinant human monoclonal IgG1 antibody against programmed death ligand-1)',\n",
       "       'axicabtagene ciloleucel', 'azacitidine', 'Azacitidine',\n",
       "       'aztreonam', 'baclofen', 'Balsalazide disodium', 'Basiliximab',\n",
       "       'bedaquiline', 'belantamab mafodotin-blmf', 'belatacept',\n",
       "       'Belinostat', 'belumosudil', 'belzutifan',\n",
       "       'bendamustine for 50 ml admixture',\n",
       "       'bendamustine for 50ml admixture', 'bendamustine hydrochloride',\n",
       "       'Bendamustine hydrochloride', 'benznidazole',\n",
       "       'Benzoate and phenylacetate', 'benzoate/phenylacetate',\n",
       "       'Beractant', 'berotralstat', 'Betaine', 'bevacizumab',\n",
       "       'Bexarotene', 'bicarbonate infusate',\n",
       "       'bictegravir, emtricitabine, and tenofovir alafenamide',\n",
       "       'bictegravir/emtricitabine/tenofovir alafenamide',\n",
       "       'Bleomycin sulfate', 'blinatumomab', 'bortezomib', 'bosutinib',\n",
       "       'Botulinum toxin type A', 'botulinum toxin type A',\n",
       "       'Botulinum toxin type B',\n",
       "       'botulism antitoxin heptavalent (A, B, C, D, E, F, G) (Equine)',\n",
       "       'Botulism immune globulin', 'brentuximab vedotin',\n",
       "       'Brentuximab vedotin', 'brexucabtagene autoleucel',\n",
       "       'brigatinib; brigatinib',\n",
       "       'Brilliant Blue G Ophthalmic Solution 0.025%', 'brincidofovir',\n",
       "       'budesonide',\n",
       "       'Buffered intrathecal electrolyte/dextrose injection',\n",
       "       'buprenorphine in combination with naloxone', 'burosumab-twza',\n",
       "       'Busulfan',\n",
       "       'C1 esterase inhibitor (human); C1 esterase inhibitor (human)',\n",
       "       'C1 Esterase Inhibitor Subcutaneous [Human]',\n",
       "       'C1-esterase inhibitor (recombinant)',\n",
       "       'C1-esterase-inhibitor, human, pasteurized', 'cabozantinib',\n",
       "       'Caffeine', 'Calcitonin-human for injection', 'Calcium acetate',\n",
       "       'calcium, magnesium, potassium, and sodium oxybates', 'calfactant',\n",
       "       'canakinumab', 'cannabidiol', 'Caplacizumab', 'capmatinib',\n",
       "       'capsaicin', 'carfilzomib', 'carglumic acid', 'casimersen',\n",
       "       'cedazuridine and decitabine', 'cenegermin-bkbj',\n",
       "       'Centruroides immune F(ab)2',\n",
       "       'Ceramide trihexosidase/alpha-galactosidase A', 'ceritinib',\n",
       "       'cerliponase alfa', 'cetuximab', 'chenodiol', 'cholic acid',\n",
       "       'ciltacabtagene autoleucel)', 'cinacalcet',\n",
       "       'Citric acid, glucono-delta-lactone and magnesium carbonate',\n",
       "       'Cladribine', 'clobazam', 'clofarabine', 'Clofazimine',\n",
       "       'Clonidine', 'Coagulation factor IX',\n",
       "       'Coagulation Factor IX (human)',\n",
       "       'Coagulation Factor IX (recombinant)',\n",
       "       'coagulation factor IX (recombinant)',\n",
       "       'Coagulation factor IX (recombinant), Fc fusion protein',\n",
       "       'Coagulation factor VIIa (recombinant)',\n",
       "       'Coagulation Factor VIIa (Recombinant)',\n",
       "       'coagulation factor VIIa (recombinant)',\n",
       "       'Coagulation factor X (human)',\n",
       "       'Coagulation factor Xa (recombinant), inactivated-zhzo',\n",
       "       'coagulation factor XIII A-subunit (recombinant)', 'cobicistat',\n",
       "       'cobimetinib', 'coccidioidin SD Skin Test Antigen', 'colchicine',\n",
       "       'Colfosceril palmitate, cetyl alcohol, tyloxapol',\n",
       "       'collagenase clostridium histolyticum',\n",
       "       'Combination of nivolumab and ipilimumab', 'copanlisib',\n",
       "       'copper Cu 64 dotatate', 'Corticorelin ovine triflutate',\n",
       "       'crizanlizumab', 'crizotinib', 'Cromolyn sodium',\n",
       "       'Cromolyn sodium 4% ophthalmic solution',\n",
       "       \"Crotalidae Immune F(ab')2 (Equine)\", 'cyclosporine', 'Cysteamine',\n",
       "       'cysteamine enteric coated', 'Cysteamine hydrochloride',\n",
       "       'Cytarabine liposomal',\n",
       "       'Cytarabine:daunorubicin liposome injection; daunorubicin and cytarabine (liposome); daunorubicin and cytarabine liposome for injection',\n",
       "       'Cytomegalovirus immune globulin (human)',\n",
       "       'd6-tetrabenazine, deutetrabenazine', 'dabrafenib',\n",
       "       'dabrafenib and trametinib', 'Daclizumab', 'dacomitinib',\n",
       "       'dalfampridine', 'dantrolene sodium suspension for injection',\n",
       "       'daratumumab', 'daratumumab and hyaluronidase-fihj', 'Dasatinib',\n",
       "       'dasatinib', 'Daunorubicin citrate liposome injection',\n",
       "       'decitabine', 'Deferasirox', 'deferasirox', 'deferiprone',\n",
       "       'defibrotide', 'deflazacort', 'dehydrated alcohol',\n",
       "       'denileukin diftitox', 'denosumab', 'Desmopressin acetate',\n",
       "       'dexamethasone', 'dexamethasone intravitreal implant',\n",
       "       'dexrazoxane', 'Dexrazoxane', 'diazepam (intranasal)',\n",
       "       'Diazepam viscous solution for rectal administration',\n",
       "       'dichlorphenamide', 'Diethylenetriaminepentaacetic acid (DTPA)',\n",
       "       'difluprednate', 'Digoxin immune FAB (Ovine)', 'dinutuximab',\n",
       "       'Dornase alfa', 'doxorubicin HCL liposome injection',\n",
       "       'Doxorubicin liposome', 'Dronabinol', 'droxidopa', 'dupilumab',\n",
       "       'durvalumab', 'duvelisib', 'ecallantide; ecallantide',\n",
       "       'eculizumab', 'edaravone', 'efgartigimod alfa-fcab',\n",
       "       'Eflornithine HCl', 'elapegademase-lvlr',\n",
       "       'elexacaftor, tezacaftor, and ivacaftor; ivacaftor',\n",
       "       'elexacaftor/tezacaftor/ivacaftor', 'eliglustat',\n",
       "       'elosulfase alfa', 'elotuzumab', 'eltrombopag', 'Emapalumab-lzsg',\n",
       "       'emicizumab-kxwh', 'emtricitabine and tenofovir alafenamide',\n",
       "       'emtricitabine and tenofovir alafenamide combination',\n",
       "       'enasidenib', 'encorafenib + binimetinib', 'entrectinib',\n",
       "       'Epirubicin', 'Epoetin alfa', 'Epoprostenol', 'epoprostenol',\n",
       "       'eribulin mesylate', 'Erwinia L-asparaginase', 'etanercept',\n",
       "       'eteplirsen', 'Ethanolamine oleate', 'ethiodized oil injection',\n",
       "       'Etidronate disodium', 'everolimus', 'evinacumab-dgnb',\n",
       "       'evolocumab', 'Exemestane', 'factor XIII concentrate (human)',\n",
       "       'fam-trastuzumab deruxtecan-nxki', 'Fedratinib', 'Felbamate',\n",
       "       'fenfluramine', 'fenfluramine HCI', 'fexinidazole', 'fidaxomicin',\n",
       "       'Filgrastim', 'filgrastim', 'fish oil triglycerides',\n",
       "       'Fludarabine phosphate', 'Fludarabine phosphate oral tablets',\n",
       "       'Fluocinolone', 'Follitropin alfa, recombinant', 'fomepizole',\n",
       "       'fosdenopterin', 'Fosphenytoin',\n",
       "       'fostamatinib disodium hexahydrate', 'gabapentin',\n",
       "       'gabapentin enacarbil', 'Gallium nitrate injection',\n",
       "       'Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide',\n",
       "       'Gallium-68 (DOTA0-Phel-Tyr3)octreotide', 'ganaxolone',\n",
       "       'ganciclovir', 'Ganciclovir intravitreal implant',\n",
       "       'Ganciclovir sodium', 'gefitinib', 'Gemtuzumab ozogamicin',\n",
       "       'gilteritinib', 'givosiran', 'Glasdegib', 'glatiramer acetate',\n",
       "       'glecaprevir and pibrentasvir', 'glucarpidase', 'Glutamine',\n",
       "       'glycerol phenylbutyrate', 'glycopyrrolate', 'golimumab',\n",
       "       'golodirsen', 'Gonadorelin acetate', 'Halofantrine', 'Hemin',\n",
       "       'hepatitis B immune globulin (human)', 'Histrelin',\n",
       "       'Histrelin acetate', 'human fibrinogen concentrate, pasteurized',\n",
       "       'Human plasma coagulation Factor VIII and human plasma von Willebrand Factor',\n",
       "       'Hydrocortisone', 'Hydroxocobalamin',\n",
       "       'hydroxycarbamide (hydroxyurea)', 'hydroxyprogesterone caproate',\n",
       "       'Hydroxyurea', 'ibalizumab', 'ibritumomab tiuxetan', 'ibrutinib',\n",
       "       'Ibuprofen lysine', 'icatibant',\n",
       "       'Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution',\n",
       "       'Idarubicin HCl for injection', 'idarucizumab',\n",
       "       'idecabtagene vicleucel', 'idelalisib', 'idursulfase',\n",
       "       'Ifosfamide', 'Iloprost inhalation solution', 'Imatinib',\n",
       "       'imatinib', 'imatinib mesylate', 'Imatinib mesylate',\n",
       "       'Imiglucerase', 'Immune Globulin (Human)',\n",
       "       'immune globulin infusion (human)',\n",
       "       'Immune Globulin Intravenous (Human)',\n",
       "       'immune globulin intravenous (human)',\n",
       "       'Immune globulin intravenous, human',\n",
       "       'Immune Globulin Subcutaneous (Human), 20% Liquid', 'inebilizumab',\n",
       "       'infigratinib', 'infliximab', 'Infliximab', 'Inotersen',\n",
       "       'inotuzumab ozogamicin', 'Interferon alfa-2a',\n",
       "       'Interferon alfa-2a (recombinant)',\n",
       "       'Interferon alfa-2b (recombinant)', 'Interferon beta-1a',\n",
       "       'Interferon beta-1b', 'Interferon gamma 1-b',\n",
       "       'Interferon gamma-1b', 'intravenous carbamazepine',\n",
       "       'Iobenguane I 123', 'Iobenguane I 131', 'Iobenguane Sulfate I 131',\n",
       "       'ipilimumab', 'irinotecan liposome injection',\n",
       "       'iron(III)-hexacyanoferrate(II)', 'isatuximab', 'isatuximab-irfc',\n",
       "       'isavuconazonium sulfate', 'ivabradine', 'ivacaftor', 'ivosidenib',\n",
       "       'ixazomib citrate',\n",
       "       'Japanese encephalitis vaccine, inactivated, adsorbed',\n",
       "       'L-glutamine', 'Lamotrigine', 'lanadelumab-flyo', 'Lanreotide',\n",
       "       'lanreotide acetate', 'laronidase', 'larotrectinib',\n",
       "       'ledipasvir/sofosbuvir', 'lenalidomide', 'lenvatinib', 'Lepirudin',\n",
       "       'letermovir', 'Leucovorin', 'Leuprolide acetate', 'Levocarnitine',\n",
       "       'levodopa and carbidopa', 'levoketoconazole', 'levoleucovorin',\n",
       "       'Levoleucovorin', 'Levomethadyl acetate hydrochloride',\n",
       "       'Lidocaine patch 5%', 'Liothyronine sodium injection',\n",
       "       'liposomal amikacin', 'Liposomal amphotericin B',\n",
       "       'lisocabtagene maraleucel', 'Lodoxamide tromethamine',\n",
       "       'lomitapide', 'lonafarnib', 'lonapegsomatropin-tcgd',\n",
       "       'loncastuximab tesirine-lpyl', 'lorlatinib', 'Lorlatinib',\n",
       "       'lumacaftor/ivacaftor', 'lumasiran', 'lurbinectedin',\n",
       "       'Luspatercept', 'Luspatercept-aamt', 'lutetium Lu 177 dotatate',\n",
       "       'macimorelin acetate', 'macitentan', 'Mafenide acetate solution',\n",
       "       'MANNITOL', 'maralixibat', 'maribavir', 'mavacamten',\n",
       "       'mebendazole', 'Mecasermin', 'mecasermin rinfabate',\n",
       "       'meclorethamine', 'mefloquine HCL', 'Megestrol acetate',\n",
       "       'meloxicam', 'Melphalan', 'melphalan', 'melphalan flufenamide',\n",
       "       'mepolizumab', 'mercaptopurine oral solution',\n",
       "       'mesalamine; 5-aminosalicylic acid', 'Mesna',\n",
       "       'methotrexate oral solution', 'Methotrexate sodium',\n",
       "       'methylene blue0.5%', 'metreleptin', 'Metronidazole (topical)',\n",
       "       'midazolam', 'Midodrine HCl', 'midostaurin', 'mifepristone',\n",
       "       'migalastat hydrochloride', 'miglustat', 'miltefosine',\n",
       "       'mipomersen', 'mitapivat', 'mitomycin', 'mitomycin-C',\n",
       "       'Mitoxantrone', 'Mitoxantrone HCl', 'mobocertinib', 'Modafinil',\n",
       "       'mogamulizumab', 'Monooctanoin',\n",
       "       'Morphine sulfate concentrate (preservative free)',\n",
       "       'moxetumomab pasudotox-tdfk', 'moxidectin',\n",
       "       'multi-vitamin infusion without vitamin K',\n",
       "       'N-acetylgalactosamine-4-sulfatase, recombinant human',\n",
       "       'Nafarelin acetate', 'Naltrexone HCl', 'naxitamab-gqgk',\n",
       "       'necitumumab', 'nelarabine', 'nifurtimox', 'nilotinib',\n",
       "       'nilotinib; nilotinib; nilotinib', 'nimodipine', 'nintedanib',\n",
       "       'niraparib', 'nitazoxanide', 'Nitazoxanide', 'Nitisinone',\n",
       "       'Nitric oxide', 'nitric oxide', 'nivolumab',\n",
       "       'nivolumab and ipilimumab', 'nivolumab and relatlimab-rmbw',\n",
       "       'nusinersen', 'obeticholic acid', 'obiltoxaximab', 'obinutuzumab',\n",
       "       'Octreotide', 'octreotide (oral)', 'odevixibat', 'ofatumumab',\n",
       "       'Ofloxacin', 'olaparib', 'olaratumab', 'omacetaxine mepesuccinate',\n",
       "       'onasemnogene abeparvovec', 'Oprelvekin', 'osilodrostat',\n",
       "       'osimertinib', 'Paclitaxel', 'paclitaxel protein-bound particles',\n",
       "       'pacritinib', 'pafolacianine', 'panobinostat',\n",
       "       'parathyroid hormone', 'paricalcitol', 'pasireotide', 'patisiran',\n",
       "       'pazopanib', 'Pegademase bovine', 'Pegaspargase', 'pegcetacoplan',\n",
       "       'Pegfilgrastim', 'peginterferon alfa-2b', 'pegloticase',\n",
       "       'pegvaliase-pqpz', 'Pegvisomant', 'pembrolizumab',\n",
       "       'pemetrexed disodium', 'Pemigatinib', 'Pentamidine isethionate',\n",
       "       'Pentastarch', 'Pentosan polysulfate sodium',\n",
       "       'pentostatin for injection', 'pexidartinib', 'phoxillum',\n",
       "       'Pilocarpine', 'Pilocarpine HCl', 'pirfenidone', 'Pitolisant',\n",
       "       'pitolisant', 'plasminogen, human-tvmh', 'plerixafor',\n",
       "       'polatuzumab vedotin-piiq', 'polifeprosan 20 with carmustine',\n",
       "       'pomalidomide', 'ponatinib', 'porfimer', 'Porfimer sodium',\n",
       "       'posaconazole', 'Potassium citrate',\n",
       "       'Potassium Iodide Oral Solution', 'pralatrexate', 'pralsetinib',\n",
       "       'Pretomanid', 'propranolol', 'Protein C concentrate',\n",
       "       'prothrombin complex concentrate (human)',\n",
       "       'Pulmonary surfactant replacement, porcine', 'quinine Sulfate',\n",
       "       'raloxifene', 'ramucirumab', 'rasburicase', 'RAVULIZUMAB',\n",
       "       'Ravulizumab-cwvz', 'ravulizumab-cwvz', 'raxibacumab',\n",
       "       'recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)',\n",
       "       'Recombinant human acid alpha-glucosidase; alglucosidase alfa',\n",
       "       'recombinant human antithrombin',\n",
       "       'Recombinant human luteinizing hormone',\n",
       "       'recombinant von Willebrand factor (rhVWF)', 'regorafenib',\n",
       "       'repository corticotropin or adrenocorticotropic hormone',\n",
       "       'Respiratory syncytial virus immune globulin (Human)',\n",
       "       'Rho (D) immune globulin intravenous (human)', 'ribavirin',\n",
       "       'riboflavin ophthalmic solution & ultraviolet A',\n",
       "       'riboflavin ophthalmic solution ultraviolet-A (UVA) irradiation',\n",
       "       'Rifabutin', 'Rifampin', 'Rifampin, isoniazid, pyrazinamide',\n",
       "       'Rifapentine', 'rifaximin', 'rilonacept', 'Rilonacept', 'Riluzole',\n",
       "       'riluzole oral film', 'riluzole oral suspension', 'riociguat',\n",
       "       'Ripretinib', 'risdiplam', 'Ritonavir powder for oral suspension',\n",
       "       'rituximab', 'rituximab and recombinant human hyaluronidase',\n",
       "       'romidepsin', 'romiplostim', 'ropeginterferon alfa-2b-njft',\n",
       "       'rosuvastatin', 'rucaparib', 'rufinamide', 'ruxolitinib',\n",
       "       'ruxolitinib phosphate', 'Sacrosidase', 'sapropterin',\n",
       "       'Sargramostim', 'sargramostim', 'satralizumab-mwge',\n",
       "       'Satumomab pendetide', 'sebelipase alfa', 'Selegiline HCl',\n",
       "       'selexipag', 'selinexor', 'selpercatinib', 'selumetinib',\n",
       "       'Sermorelin acetate', 'setmelanotide', 'siltuximab', 'sirolimus',\n",
       "       'sirolimus protein-bound particles for injectable suspension (albumin-bound)',\n",
       "       'sodium nitrite and sodium thiosulfate', 'sodium oxybate',\n",
       "       'sodium phenylbutyrate',\n",
       "       'sodium sulfate, potassium sulfate, and magnesium sulfate',\n",
       "       'sofosbuvir', 'sofosbuvir and velpatasvir',\n",
       "       'sofosbuvir/velpatasvir', 'Solriamfetol', 'Somatrem for injection',\n",
       "       'Somatropin', 'Somatropin (r-DNA)', 'Somatropin (rDNA origin)',\n",
       "       'Somatropin (rDNA origin) injection', 'Somatropin for injection',\n",
       "       'somatropin [rDNA]', 'Somatropin [rDNA]', 'Sorafenib', 'sorafenib',\n",
       "       'sotalol (IV)', 'Sotalol HCl', 'sotorasib', 'Sterile talc',\n",
       "       'Sterile talc powder', 'stiripentol', 'Succimer', 'Sulfadiazine',\n",
       "       'sutimlimab-jome', 'Synthetic human secretin',\n",
       "       'Synthetic porcine secretin', 'Tacrolimus', 'tacrolimus',\n",
       "       'tacrolimus extended-release capsules', 'tadalafil',\n",
       "       'tafamidis meglumine', 'tafasitamab', 'tafenoquine',\n",
       "       'Tagraxofusp-erzs', 'Taliglucerase alfa',\n",
       "       'talimogene laherparepvec', 'tasimelteon', 'tazemetostat',\n",
       "       'tebentafusp-tebn', 'technetium Tc 99m tilmanocept',\n",
       "       'Technetium Tc99m sulfur colloid injection, lyophilized',\n",
       "       'tecovirimat',\n",
       "       'teduglutide [rDNA origin]; teduglutide [rDNA origin]',\n",
       "       'telotristat etiprate', 'temozolomide', 'Temsirolimus',\n",
       "       'Teniposide', 'tenofovir', 'tepotinib', 'teprotumumab',\n",
       "       'Teriparatide', 'Tetrabenazine',\n",
       "       'Tezacaftor and Ivacaftor combination therapy',\n",
       "       'tezacaftor/ivacaftor; ivacaftor', 'Thalidomide', 'Thiotepa',\n",
       "       'Thyrotropin alfa', 'Thyrotropin alpha', 'tinidazole',\n",
       "       'Tinidazole', 'Tiopronin', 'tisagenlecleucel-T',\n",
       "       'Tobramycin for inhalation', 'tocilizumab', 'tolvaptan',\n",
       "       'Topiramate', 'Toremifene',\n",
       "       'Tositumomab and iodine I 131 tositumomab', 'trabectedin',\n",
       "       'trametinib', 'trametinib and dabrafenib', 'tranexamic acid',\n",
       "       'trastuzumab', 'treprostinil', 'treprostinil (inhalational)',\n",
       "       'Tretinoin', 'triclabendazole', 'Trientine HCl',\n",
       "       'trientine tetrahydrochloride', 'trifluridine/tipiracil',\n",
       "       'triheptanoin', 'Trimetrexate glucuronate', 'triptorelin pamoate',\n",
       "       'Trypan blue', 'tucatinib', 'umbralisib', 'uridine triacetate',\n",
       "       'Urofollitropin', 'Ursodiol',\n",
       "       'Vaccinia Immune Globulin (Human) Intravenous', 'Valrubicin',\n",
       "       'vandetanib', 'Varicella Zoster Immune Globulin (Human)',\n",
       "       'velaglucerase-alfa', 'vemurafenib', 'venetoclax',\n",
       "       'vestronidase alfa-vjbk', 'vigabatrin', 'viltolarsen',\n",
       "       'vinCRIStine sulfate LIPOSOME injection',\n",
       "       'von Willebrand factor (recombinant)',\n",
       "       'voretigene neparvovec-rzyl', 'vorinostat', 'vosoritide',\n",
       "       'Voxelotor', 'voxelotor', 'Zalcitabine', 'zanubrutinib',\n",
       "       'zidovudine', 'Zinc acetate', 'Zoledronate',\n",
       "       'Note: Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.'],\n",
       "      dtype=object)"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#To see all data entries of the Generic Name column\n",
    "df['Generic Name'].unique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "4d35e0ec",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Generic Name</th>\n",
       "      <th>Trade Name</th>\n",
       "      <th>Date Designated</th>\n",
       "      <th>Orphan Designation</th>\n",
       "      <th>Orphan Designation Status</th>\n",
       "      <th>Approved Labeled Indication</th>\n",
       "      <th>Marketing Approval Date</th>\n",
       "      <th>Exclusivity End Date</th>\n",
       "      <th>Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)</th>\n",
       "      <th>Sponsor Company</th>\n",
       "      <th>Sponsor Address 1</th>\n",
       "      <th>Sponsor City</th>\n",
       "      <th>Sponsor State</th>\n",
       "      <th>Sponsor Zip</th>\n",
       "      <th>Sponsor Country</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1052</th>\n",
       "      <td>zanubrutinib</td>\n",
       "      <td>Brukinsa</td>\n",
       "      <td>08/24/2020</td>\n",
       "      <td>Treatment of extranodal marginal zone lymphoma...</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Treatment of adult patients with relapsed or r...</td>\n",
       "      <td>09/14/2021</td>\n",
       "      <td>09/14/2028</td>\n",
       "      <td>Treatment of adult patients with relapsed or r...</td>\n",
       "      <td>BeiGene USA, Inc.</td>\n",
       "      <td>2955 Campus Drive</td>\n",
       "      <td>San Mateo</td>\n",
       "      <td>California</td>\n",
       "      <td>94403</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1053</th>\n",
       "      <td>zanubrutinib</td>\n",
       "      <td>Brukinsa</td>\n",
       "      <td>08/24/2020</td>\n",
       "      <td>Treatment of nodal marginal zone lymphoma</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Treatment of adult patients with relapsed or r...</td>\n",
       "      <td>09/14/2021</td>\n",
       "      <td>09/14/2028</td>\n",
       "      <td>Treatment of adult patients with relapsed or r...</td>\n",
       "      <td>BeiGene USA, Inc.</td>\n",
       "      <td>2955 Campus Drive</td>\n",
       "      <td>San Mateo</td>\n",
       "      <td>California</td>\n",
       "      <td>94403</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1054</th>\n",
       "      <td>zidovudine</td>\n",
       "      <td>Retrovir</td>\n",
       "      <td>07/17/1985</td>\n",
       "      <td>Treatment of AIDS</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Management of certain adult patients with symp...</td>\n",
       "      <td>03/19/1987</td>\n",
       "      <td>03/19/1994</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Glaxo Wellcome Inc.</td>\n",
       "      <td>5 Moore Drive</td>\n",
       "      <td>Research Triangle Park</td>\n",
       "      <td>North Carolina</td>\n",
       "      <td>27709</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1055</th>\n",
       "      <td>Zinc acetate</td>\n",
       "      <td>Galzin</td>\n",
       "      <td>11/06/85</td>\n",
       "      <td>Treatment of Wilson's disease.</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>For maintenance treatment of patients with Wil...</td>\n",
       "      <td>01/28/1997</td>\n",
       "      <td>01/28/2004</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Lemmon Company</td>\n",
       "      <td>1510 Delp Drive</td>\n",
       "      <td>Kulpsville</td>\n",
       "      <td>Pennsylvania</td>\n",
       "      <td>19443</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1056</th>\n",
       "      <td>Zoledronate</td>\n",
       "      <td>Zometa, Zabel</td>\n",
       "      <td>08/18/2000</td>\n",
       "      <td>Treatment of tumor induced hypercalcemia.</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Treatment of hypercalcemia of malignancy.</td>\n",
       "      <td>08/20/2001</td>\n",
       "      <td>08/20/2008</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Novartis Pharmaceuticals Corp.</td>\n",
       "      <td>59 Route 10</td>\n",
       "      <td>East Hanover</td>\n",
       "      <td>New Jersey</td>\n",
       "      <td>7936</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "      Generic Name     Trade Name Date Designated  \\\n",
       "1052  zanubrutinib       Brukinsa      08/24/2020   \n",
       "1053  zanubrutinib       Brukinsa      08/24/2020   \n",
       "1054    zidovudine       Retrovir      07/17/1985   \n",
       "1055  Zinc acetate         Galzin        11/06/85   \n",
       "1056   Zoledronate  Zometa, Zabel      08/18/2000   \n",
       "\n",
       "                                     Orphan Designation  \\\n",
       "1052  Treatment of extranodal marginal zone lymphoma...   \n",
       "1053          Treatment of nodal marginal zone lymphoma   \n",
       "1054                                  Treatment of AIDS   \n",
       "1055                     Treatment of Wilson's disease.   \n",
       "1056          Treatment of tumor induced hypercalcemia.   \n",
       "\n",
       "     Orphan Designation Status  \\\n",
       "1052       Designated/Approved   \n",
       "1053       Designated/Approved   \n",
       "1054       Designated/Approved   \n",
       "1055       Designated/Approved   \n",
       "1056       Designated/Approved   \n",
       "\n",
       "                            Approved Labeled Indication  \\\n",
       "1052  Treatment of adult patients with relapsed or r...   \n",
       "1053  Treatment of adult patients with relapsed or r...   \n",
       "1054  Management of certain adult patients with symp...   \n",
       "1055  For maintenance treatment of patients with Wil...   \n",
       "1056          Treatment of hypercalcemia of malignancy.   \n",
       "\n",
       "     Marketing Approval Date Exclusivity End Date  \\\n",
       "1052              09/14/2021           09/14/2028   \n",
       "1053              09/14/2021           09/14/2028   \n",
       "1054              03/19/1987           03/19/1994   \n",
       "1055              01/28/1997           01/28/2004   \n",
       "1056              08/20/2001           08/20/2008   \n",
       "\n",
       "     Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)  \\\n",
       "1052  Treatment of adult patients with relapsed or r...                                           \n",
       "1053  Treatment of adult patients with relapsed or r...                                           \n",
       "1054                                                NaN                                           \n",
       "1055                                                NaN                                           \n",
       "1056                                                NaN                                           \n",
       "\n",
       "                     Sponsor Company  Sponsor Address 1  \\\n",
       "1052               BeiGene USA, Inc.  2955 Campus Drive   \n",
       "1053               BeiGene USA, Inc.  2955 Campus Drive   \n",
       "1054             Glaxo Wellcome Inc.      5 Moore Drive   \n",
       "1055                  Lemmon Company    1510 Delp Drive   \n",
       "1056  Novartis Pharmaceuticals Corp.        59 Route 10   \n",
       "\n",
       "                Sponsor City   Sponsor State Sponsor Zip Sponsor Country  \n",
       "1052               San Mateo      California       94403   United States  \n",
       "1053               San Mateo      California       94403   United States  \n",
       "1054  Research Triangle Park  North Carolina       27709   United States  \n",
       "1055              Kulpsville    Pennsylvania       19443   United States  \n",
       "1056            East Hanover      New Jersey        7936   United States  "
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Drop last row as no data present apart from the caption about exclusivity protected indications\n",
    "df.drop([1057], inplace = True)\n",
    "df.tail()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "8e646935",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Generic Name</th>\n",
       "      <th>Trade Name</th>\n",
       "      <th>Date Designated</th>\n",
       "      <th>Orphan Designation</th>\n",
       "      <th>Orphan Designation Status</th>\n",
       "      <th>Approved Labeled Indication</th>\n",
       "      <th>Marketing Approval Date</th>\n",
       "      <th>Exclusivity End Date</th>\n",
       "      <th>Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)</th>\n",
       "      <th>Sponsor Company</th>\n",
       "      <th>Sponsor Address 1</th>\n",
       "      <th>Sponsor City</th>\n",
       "      <th>Sponsor State</th>\n",
       "      <th>Sponsor Zip</th>\n",
       "      <th>Sponsor Country</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>bosentan</td>\n",
       "      <td>Tracleer</td>\n",
       "      <td>2000-10-06 00:00:00</td>\n",
       "      <td>Treatment of pulmonary arterial hypertension</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Treatment of pulmonary arterial hypertension.</td>\n",
       "      <td>2001-11-20 00:00:00</td>\n",
       "      <td>11/20/2008</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Actelion Pharmaceuticals Ltd</td>\n",
       "      <td>1840 Gateway Drive</td>\n",
       "      <td>Cherry Hill</td>\n",
       "      <td>New Jersey</td>\n",
       "      <td>8002</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>bosentan</td>\n",
       "      <td>Tracleer</td>\n",
       "      <td>2000-10-06 00:00:00</td>\n",
       "      <td>Treatment of pulmonary arterial hypertension</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Treatment of pulmonary arterial hypertension (...</td>\n",
       "      <td>2017-09-05 00:00:00</td>\n",
       "      <td>9/05/24</td>\n",
       "      <td>Treatment of pulmonary arterial hypertension (...</td>\n",
       "      <td>Actelion Pharmaceuticals Ltd</td>\n",
       "      <td>1840 Gateway Drive</td>\n",
       "      <td>Cherry Hill</td>\n",
       "      <td>New Jersey</td>\n",
       "      <td>8002</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>(tisagenlecleucel) Autologous T Cells transduc...</td>\n",
       "      <td>Kymriah (tisagenlecleucel)</td>\n",
       "      <td>2014-01-31 00:00:00</td>\n",
       "      <td>For the treatment of Acute Lymphoblastic Leukemia</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Treatment of patients up to 25 years of age wi...</td>\n",
       "      <td>2017-08-30 00:00:00</td>\n",
       "      <td>08/30/2024</td>\n",
       "      <td>Treatment of patients up to 25 years of age wi...</td>\n",
       "      <td>Novartis Pharmaceuticals Corporation</td>\n",
       "      <td>One Health Plaza,</td>\n",
       "      <td>East Hanover</td>\n",
       "      <td>New Jersey</td>\n",
       "      <td>7936</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>5-aminolevulinic acid</td>\n",
       "      <td>Gleolan</td>\n",
       "      <td>2013-01-15 00:00:00</td>\n",
       "      <td>Visualization of malignant tissue during surge...</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Optical imaging agent indicated in patients wi...</td>\n",
       "      <td>2017-06-06 00:00:00</td>\n",
       "      <td>6/06/24</td>\n",
       "      <td>Optical imaging agent indicated in patients wi...</td>\n",
       "      <td>NX Development Corporation</td>\n",
       "      <td>1827 South Bayshore Lane</td>\n",
       "      <td>Miami</td>\n",
       "      <td>Florida</td>\n",
       "      <td>33133</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>abatacept</td>\n",
       "      <td>Orencia</td>\n",
       "      <td>2017-12-26 00:00:00</td>\n",
       "      <td>Prevention of graft versus host disease</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>prophylaxis of acute graft versus host disease...</td>\n",
       "      <td>2021-12-15 00:00:00</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Bristol-Myers Squibb Co.</td>\n",
       "      <td>P. O. Box 5326</td>\n",
       "      <td>Princeton</td>\n",
       "      <td>New Jersey</td>\n",
       "      <td>8543</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        Generic Name  \\\n",
       "0                                           bosentan   \n",
       "1                                           bosentan   \n",
       "2  (tisagenlecleucel) Autologous T Cells transduc...   \n",
       "3                              5-aminolevulinic acid   \n",
       "4                                          abatacept   \n",
       "\n",
       "                   Trade Name      Date Designated  \\\n",
       "0                    Tracleer  2000-10-06 00:00:00   \n",
       "1                    Tracleer  2000-10-06 00:00:00   \n",
       "2  Kymriah (tisagenlecleucel)  2014-01-31 00:00:00   \n",
       "3                     Gleolan  2013-01-15 00:00:00   \n",
       "4                     Orencia  2017-12-26 00:00:00   \n",
       "\n",
       "                                  Orphan Designation  \\\n",
       "0       Treatment of pulmonary arterial hypertension   \n",
       "1       Treatment of pulmonary arterial hypertension   \n",
       "2  For the treatment of Acute Lymphoblastic Leukemia   \n",
       "3  Visualization of malignant tissue during surge...   \n",
       "4            Prevention of graft versus host disease   \n",
       "\n",
       "  Orphan Designation Status  \\\n",
       "0       Designated/Approved   \n",
       "1       Designated/Approved   \n",
       "2       Designated/Approved   \n",
       "3       Designated/Approved   \n",
       "4       Designated/Approved   \n",
       "\n",
       "                         Approved Labeled Indication Marketing Approval Date  \\\n",
       "0      Treatment of pulmonary arterial hypertension.     2001-11-20 00:00:00   \n",
       "1  Treatment of pulmonary arterial hypertension (...     2017-09-05 00:00:00   \n",
       "2  Treatment of patients up to 25 years of age wi...     2017-08-30 00:00:00   \n",
       "3  Optical imaging agent indicated in patients wi...     2017-06-06 00:00:00   \n",
       "4  prophylaxis of acute graft versus host disease...     2021-12-15 00:00:00   \n",
       "\n",
       "  Exclusivity End Date  \\\n",
       "0           11/20/2008   \n",
       "1              9/05/24   \n",
       "2           08/30/2024   \n",
       "3              6/06/24   \n",
       "4                  NaN   \n",
       "\n",
       "  Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)  \\\n",
       "0                                                NaN                                           \n",
       "1  Treatment of pulmonary arterial hypertension (...                                           \n",
       "2  Treatment of patients up to 25 years of age wi...                                           \n",
       "3  Optical imaging agent indicated in patients wi...                                           \n",
       "4                                                NaN                                           \n",
       "\n",
       "                        Sponsor Company         Sponsor Address 1  \\\n",
       "0          Actelion Pharmaceuticals Ltd        1840 Gateway Drive   \n",
       "1          Actelion Pharmaceuticals Ltd        1840 Gateway Drive   \n",
       "2  Novartis Pharmaceuticals Corporation         One Health Plaza,   \n",
       "3            NX Development Corporation  1827 South Bayshore Lane   \n",
       "4              Bristol-Myers Squibb Co.            P. O. Box 5326   \n",
       "\n",
       "   Sponsor City Sponsor State Sponsor Zip Sponsor Country  \n",
       "0   Cherry Hill    New Jersey        8002   United States  \n",
       "1   Cherry Hill    New Jersey        8002   United States  \n",
       "2  East Hanover    New Jersey        7936   United States  \n",
       "3         Miami       Florida       33133   United States  \n",
       "4     Princeton    New Jersey        8543   United States  "
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#change Date Designated & Marketing Approval Date columns to datetime format\n",
    "df.loc[:, (\"Date Designated\", \"Marketing Approval Date\")] = df.loc[:, (\"Date Designated\", \"Marketing Approval Date\")].astype(\"datetime64\")\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "4285a01a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Generic Name</th>\n",
       "      <th>Trade Name</th>\n",
       "      <th>Date Designated</th>\n",
       "      <th>Orphan Designation</th>\n",
       "      <th>Orphan Designation Status</th>\n",
       "      <th>Approved Labeled Indication</th>\n",
       "      <th>Marketing Approval Date</th>\n",
       "      <th>Exclusivity End Date</th>\n",
       "      <th>Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)</th>\n",
       "      <th>Sponsor Company</th>\n",
       "      <th>Sponsor Address 1</th>\n",
       "      <th>Sponsor City</th>\n",
       "      <th>Sponsor State</th>\n",
       "      <th>Sponsor Zip</th>\n",
       "      <th>Sponsor Country</th>\n",
       "      <th>Time_diff</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>bosentan</td>\n",
       "      <td>Tracleer</td>\n",
       "      <td>2000-10-06 00:00:00</td>\n",
       "      <td>Treatment of pulmonary arterial hypertension</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Treatment of pulmonary arterial hypertension.</td>\n",
       "      <td>2001-11-20 00:00:00</td>\n",
       "      <td>11/20/2008</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Actelion Pharmaceuticals Ltd</td>\n",
       "      <td>1840 Gateway Drive</td>\n",
       "      <td>Cherry Hill</td>\n",
       "      <td>New Jersey</td>\n",
       "      <td>8002</td>\n",
       "      <td>United States</td>\n",
       "      <td>410 days</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>bosentan</td>\n",
       "      <td>Tracleer</td>\n",
       "      <td>2000-10-06 00:00:00</td>\n",
       "      <td>Treatment of pulmonary arterial hypertension</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Treatment of pulmonary arterial hypertension (...</td>\n",
       "      <td>2017-09-05 00:00:00</td>\n",
       "      <td>9/05/24</td>\n",
       "      <td>Treatment of pulmonary arterial hypertension (...</td>\n",
       "      <td>Actelion Pharmaceuticals Ltd</td>\n",
       "      <td>1840 Gateway Drive</td>\n",
       "      <td>Cherry Hill</td>\n",
       "      <td>New Jersey</td>\n",
       "      <td>8002</td>\n",
       "      <td>United States</td>\n",
       "      <td>6178 days</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>(tisagenlecleucel) Autologous T Cells transduc...</td>\n",
       "      <td>Kymriah (tisagenlecleucel)</td>\n",
       "      <td>2014-01-31 00:00:00</td>\n",
       "      <td>For the treatment of Acute Lymphoblastic Leukemia</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Treatment of patients up to 25 years of age wi...</td>\n",
       "      <td>2017-08-30 00:00:00</td>\n",
       "      <td>08/30/2024</td>\n",
       "      <td>Treatment of patients up to 25 years of age wi...</td>\n",
       "      <td>Novartis Pharmaceuticals Corporation</td>\n",
       "      <td>One Health Plaza,</td>\n",
       "      <td>East Hanover</td>\n",
       "      <td>New Jersey</td>\n",
       "      <td>7936</td>\n",
       "      <td>United States</td>\n",
       "      <td>1307 days</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>5-aminolevulinic acid</td>\n",
       "      <td>Gleolan</td>\n",
       "      <td>2013-01-15 00:00:00</td>\n",
       "      <td>Visualization of malignant tissue during surge...</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Optical imaging agent indicated in patients wi...</td>\n",
       "      <td>2017-06-06 00:00:00</td>\n",
       "      <td>6/06/24</td>\n",
       "      <td>Optical imaging agent indicated in patients wi...</td>\n",
       "      <td>NX Development Corporation</td>\n",
       "      <td>1827 South Bayshore Lane</td>\n",
       "      <td>Miami</td>\n",
       "      <td>Florida</td>\n",
       "      <td>33133</td>\n",
       "      <td>United States</td>\n",
       "      <td>1603 days</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>abatacept</td>\n",
       "      <td>Orencia</td>\n",
       "      <td>2017-12-26 00:00:00</td>\n",
       "      <td>Prevention of graft versus host disease</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>prophylaxis of acute graft versus host disease...</td>\n",
       "      <td>2021-12-15 00:00:00</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Bristol-Myers Squibb Co.</td>\n",
       "      <td>P. O. Box 5326</td>\n",
       "      <td>Princeton</td>\n",
       "      <td>New Jersey</td>\n",
       "      <td>8543</td>\n",
       "      <td>United States</td>\n",
       "      <td>1450 days</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        Generic Name  \\\n",
       "0                                           bosentan   \n",
       "1                                           bosentan   \n",
       "2  (tisagenlecleucel) Autologous T Cells transduc...   \n",
       "3                              5-aminolevulinic acid   \n",
       "4                                          abatacept   \n",
       "\n",
       "                   Trade Name      Date Designated  \\\n",
       "0                    Tracleer  2000-10-06 00:00:00   \n",
       "1                    Tracleer  2000-10-06 00:00:00   \n",
       "2  Kymriah (tisagenlecleucel)  2014-01-31 00:00:00   \n",
       "3                     Gleolan  2013-01-15 00:00:00   \n",
       "4                     Orencia  2017-12-26 00:00:00   \n",
       "\n",
       "                                  Orphan Designation  \\\n",
       "0       Treatment of pulmonary arterial hypertension   \n",
       "1       Treatment of pulmonary arterial hypertension   \n",
       "2  For the treatment of Acute Lymphoblastic Leukemia   \n",
       "3  Visualization of malignant tissue during surge...   \n",
       "4            Prevention of graft versus host disease   \n",
       "\n",
       "  Orphan Designation Status  \\\n",
       "0       Designated/Approved   \n",
       "1       Designated/Approved   \n",
       "2       Designated/Approved   \n",
       "3       Designated/Approved   \n",
       "4       Designated/Approved   \n",
       "\n",
       "                         Approved Labeled Indication Marketing Approval Date  \\\n",
       "0      Treatment of pulmonary arterial hypertension.     2001-11-20 00:00:00   \n",
       "1  Treatment of pulmonary arterial hypertension (...     2017-09-05 00:00:00   \n",
       "2  Treatment of patients up to 25 years of age wi...     2017-08-30 00:00:00   \n",
       "3  Optical imaging agent indicated in patients wi...     2017-06-06 00:00:00   \n",
       "4  prophylaxis of acute graft versus host disease...     2021-12-15 00:00:00   \n",
       "\n",
       "  Exclusivity End Date  \\\n",
       "0           11/20/2008   \n",
       "1              9/05/24   \n",
       "2           08/30/2024   \n",
       "3              6/06/24   \n",
       "4                  NaN   \n",
       "\n",
       "  Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)  \\\n",
       "0                                                NaN                                           \n",
       "1  Treatment of pulmonary arterial hypertension (...                                           \n",
       "2  Treatment of patients up to 25 years of age wi...                                           \n",
       "3  Optical imaging agent indicated in patients wi...                                           \n",
       "4                                                NaN                                           \n",
       "\n",
       "                        Sponsor Company         Sponsor Address 1  \\\n",
       "0          Actelion Pharmaceuticals Ltd        1840 Gateway Drive   \n",
       "1          Actelion Pharmaceuticals Ltd        1840 Gateway Drive   \n",
       "2  Novartis Pharmaceuticals Corporation         One Health Plaza,   \n",
       "3            NX Development Corporation  1827 South Bayshore Lane   \n",
       "4              Bristol-Myers Squibb Co.            P. O. Box 5326   \n",
       "\n",
       "   Sponsor City Sponsor State Sponsor Zip Sponsor Country Time_diff  \n",
       "0   Cherry Hill    New Jersey        8002   United States  410 days  \n",
       "1   Cherry Hill    New Jersey        8002   United States 6178 days  \n",
       "2  East Hanover    New Jersey        7936   United States 1307 days  \n",
       "3         Miami       Florida       33133   United States 1603 days  \n",
       "4     Princeton    New Jersey        8543   United States 1450 days  "
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Calculate the time difference between date designated & marketing approval date\n",
    "df.loc[:, \"Time_diff\"] = (df.loc[:, 'Marketing Approval Date'] - df.loc[:, 'Date Designated'])\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "8ae5bd50",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Timedelta('1932 days 06:17:22.194891200')"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#To obtain the average time required from designation date to marketing approval date\n",
    "df_time_diff_avg = df[\"Time_diff\"].mean()\n",
    "df_time_diff_avg"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "ef6ff5bc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Time_diff</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>1057</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mean</th>\n",
       "      <td>1932 days 06:17:22.194891200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>std</th>\n",
       "      <td>1842 days 08:42:36.159085920</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>min</th>\n",
       "      <td>-2000 days +00:00:00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25%</th>\n",
       "      <td>693 days 00:00:00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50%</th>\n",
       "      <td>1480 days 00:00:00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75%</th>\n",
       "      <td>2590 days 00:00:00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>max</th>\n",
       "      <td>12215 days 00:00:00</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                          Time_diff\n",
       "count                          1057\n",
       "mean   1932 days 06:17:22.194891200\n",
       "std    1842 days 08:42:36.159085920\n",
       "min            -2000 days +00:00:00\n",
       "25%               693 days 00:00:00\n",
       "50%              1480 days 00:00:00\n",
       "75%              2590 days 00:00:00\n",
       "max             12215 days 00:00:00"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Quick overview of overall statistical summary of the whole dataset \n",
    "#for the time required from designation date to marketing approval date\n",
    "df.describe()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f66101d5",
   "metadata": {},
   "source": [
    "The average time required for a rare disease drug to progress from the initial designation phase to the final approval for marketing was about 1932 days (~5 years). The datatset was obtained from FDA for the period from 1983 till present."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "ca8fd848",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Generic Name                                                                                  string\n",
       "Trade Name                                                                                    object\n",
       "Date Designated                                                                               object\n",
       "Orphan Designation                                                                            object\n",
       "Orphan Designation Status                                                                     object\n",
       "Approved Labeled Indication                                                                   object\n",
       "Marketing Approval Date                                                                       object\n",
       "Exclusivity End Date                                                                          object\n",
       "Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)    object\n",
       "Sponsor Company                                                                               object\n",
       "Sponsor Address 1                                                                             object\n",
       "Sponsor City                                                                                  object\n",
       "Sponsor State                                                                                 object\n",
       "Sponsor Zip                                                                                   object\n",
       "Sponsor Country                                                                               object\n",
       "Time_diff                                                                                      int64\n",
       "dtype: object"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Change the data type for Generic name and Time_diff columns\n",
    "df.loc[:, \"Generic Name\"] = df.loc[:, \"Generic Name\"].astype(\"string\")\n",
    "df.loc[:, \"Time_diff\"] = df.loc[:, \"Time_diff\"].dt.days.astype(\"int\")\n",
    "df.dtypes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "ade3f373",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Generic Name</th>\n",
       "      <th>Trade Name</th>\n",
       "      <th>Date Designated</th>\n",
       "      <th>Orphan Designation</th>\n",
       "      <th>Orphan Designation Status</th>\n",
       "      <th>Approved Labeled Indication</th>\n",
       "      <th>Marketing Approval Date</th>\n",
       "      <th>Exclusivity End Date</th>\n",
       "      <th>Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)</th>\n",
       "      <th>Sponsor Company</th>\n",
       "      <th>Sponsor Address 1</th>\n",
       "      <th>Sponsor City</th>\n",
       "      <th>Sponsor State</th>\n",
       "      <th>Sponsor Zip</th>\n",
       "      <th>Sponsor Country</th>\n",
       "      <th>Time_diff</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>984</th>\n",
       "      <td>Tiopronin</td>\n",
       "      <td>Thiola</td>\n",
       "      <td>1986-01-17 00:00:00</td>\n",
       "      <td>Prevention of cystine nephrolithiasis in patie...</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>THIOLA EC is indicated, in combination with hi...</td>\n",
       "      <td>2019-06-28 00:00:00</td>\n",
       "      <td>06/28/2026</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Mission Pharmacal Company</td>\n",
       "      <td>P.O. Box 786099</td>\n",
       "      <td>San Antonio</td>\n",
       "      <td>Texas</td>\n",
       "      <td>78278</td>\n",
       "      <td>United States</td>\n",
       "      <td>12215</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>985</th>\n",
       "      <td>Tiopronin</td>\n",
       "      <td>Thiola</td>\n",
       "      <td>1986-01-17 00:00:00</td>\n",
       "      <td>Prevention of cystine nephrolithiasis in patie...</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>THIOLA is indicated, in combination with high ...</td>\n",
       "      <td>2019-06-28 00:00:00</td>\n",
       "      <td>06/28/2026</td>\n",
       "      <td>Indicated in combination with high fluid intak...</td>\n",
       "      <td>Mission Pharmacal Company</td>\n",
       "      <td>P.O. Box 786099</td>\n",
       "      <td>San Antonio</td>\n",
       "      <td>Texas</td>\n",
       "      <td>78278</td>\n",
       "      <td>United States</td>\n",
       "      <td>12215</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>agalsidase beta</td>\n",
       "      <td>Fabrazyme</td>\n",
       "      <td>1988-01-19 00:00:00</td>\n",
       "      <td>Treatment of Fabry's disease.</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>treatment of adult and pediatric patients 2 ye...</td>\n",
       "      <td>2021-03-11 00:00:00</td>\n",
       "      <td>3/11/28</td>\n",
       "      <td>treatment of pediatric patients 2 years of age...</td>\n",
       "      <td>Genzyme Corporation</td>\n",
       "      <td>50 Binney Street</td>\n",
       "      <td>Cambridge</td>\n",
       "      <td>Massachusetts</td>\n",
       "      <td>2142</td>\n",
       "      <td>United States</td>\n",
       "      <td>12105</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>741</th>\n",
       "      <td>Pegaspargase</td>\n",
       "      <td>Oncaspar; Asparlas</td>\n",
       "      <td>1989-10-20 00:00:00</td>\n",
       "      <td>Treatment of acute lymphocytic leukemia.</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>ASPARLAS is indicated as a component of a mult...</td>\n",
       "      <td>2018-12-20 00:00:00</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Servier Pharmaceuticals LLC</td>\n",
       "      <td>200 Pier Four Blvd</td>\n",
       "      <td>Boston</td>\n",
       "      <td>Massachusetts</td>\n",
       "      <td>2210</td>\n",
       "      <td>United States</td>\n",
       "      <td>10653</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>394</th>\n",
       "      <td>factor XIII concentrate (human)</td>\n",
       "      <td>Corifact</td>\n",
       "      <td>1985-01-16 00:00:00</td>\n",
       "      <td>Treatment of congenital factor XIII deficiency</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Indicated for routine prophylactic treatment a...</td>\n",
       "      <td>2013-01-24 00:00:00</td>\n",
       "      <td>01/24/2020</td>\n",
       "      <td>Peri-operative management of surgical bleeding...</td>\n",
       "      <td>CSL Behring LLC</td>\n",
       "      <td>1020 First Ave.</td>\n",
       "      <td>King of Prussia</td>\n",
       "      <td>Pennsylvania</td>\n",
       "      <td>19406</td>\n",
       "      <td>United States</td>\n",
       "      <td>10235</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>181</th>\n",
       "      <td>C1 Esterase Inhibitor Subcutaneous [Human]</td>\n",
       "      <td>HAEGARDA</td>\n",
       "      <td>1992-10-16 00:00:00</td>\n",
       "      <td>Prevention and/or treatment of acute attacks o...</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>HAEGARDA is a plasma-derived concentrate of C1...</td>\n",
       "      <td>2020-09-24 00:00:00</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CSL Behring LLC</td>\n",
       "      <td>1020 First Avenue</td>\n",
       "      <td>King of Prussia</td>\n",
       "      <td>Pennsylvania</td>\n",
       "      <td>19406</td>\n",
       "      <td>United States</td>\n",
       "      <td>10205</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>102</th>\n",
       "      <td>baclofen</td>\n",
       "      <td>OZOBAX</td>\n",
       "      <td>1991-12-16 00:00:00</td>\n",
       "      <td>Treatment of intractable spasticity due to mul...</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Treatment of spasticity resulting from multipl...</td>\n",
       "      <td>2019-09-18 00:00:00</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Metacel Pharmaceuticals, LLC</td>\n",
       "      <td>244 E Washington Street</td>\n",
       "      <td>Athens</td>\n",
       "      <td>Georgia</td>\n",
       "      <td>30601</td>\n",
       "      <td>United States</td>\n",
       "      <td>10138</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>153</th>\n",
       "      <td>botulinum toxin type A</td>\n",
       "      <td>Botox</td>\n",
       "      <td>1991-12-06 00:00:00</td>\n",
       "      <td>Treatment of dynamic muscle contracture in ped...</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>BOTOX is indicated for the treatment of upper ...</td>\n",
       "      <td>2019-06-20 00:00:00</td>\n",
       "      <td>06/20/2026</td>\n",
       "      <td>For the treatment of upper limb spasticity in ...</td>\n",
       "      <td>Allergan, Inc.</td>\n",
       "      <td>2525 Dupont Drive</td>\n",
       "      <td>Irvine</td>\n",
       "      <td>California</td>\n",
       "      <td>92623</td>\n",
       "      <td>United States</td>\n",
       "      <td>10058</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>847</th>\n",
       "      <td>rituximab</td>\n",
       "      <td>Rituxan</td>\n",
       "      <td>1994-06-13 00:00:00</td>\n",
       "      <td>Treatment of non-Hodgkin's B-cell lymphoma</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>treatment of pediatric patients aged 6 months ...</td>\n",
       "      <td>2021-12-02 00:00:00</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Genentech, Inc.</td>\n",
       "      <td>1 DNA Way, MS 242</td>\n",
       "      <td>South San Francisco</td>\n",
       "      <td>California</td>\n",
       "      <td>94080</td>\n",
       "      <td>United States</td>\n",
       "      <td>10034</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>240</th>\n",
       "      <td>coagulation factor IX (recombinant)</td>\n",
       "      <td>BeneFIX</td>\n",
       "      <td>1994-10-03 00:00:00</td>\n",
       "      <td>Treatment of hemophilia B</td>\n",
       "      <td>Designated/Approved</td>\n",
       "      <td>Routine prophylaxis to reduce the frequency of...</td>\n",
       "      <td>2021-10-05 00:00:00</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Wyeth Pharmaceuticals LLC, a subsidiary of Pfi...</td>\n",
       "      <td>235 E. 42nd St 219/9/1</td>\n",
       "      <td>New York</td>\n",
       "      <td>New York</td>\n",
       "      <td>10017</td>\n",
       "      <td>United States</td>\n",
       "      <td>9864</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                   Generic Name          Trade Name  \\\n",
       "984                                   Tiopronin              Thiola   \n",
       "985                                   Tiopronin              Thiola   \n",
       "22                              agalsidase beta           Fabrazyme   \n",
       "741                                Pegaspargase  Oncaspar; Asparlas   \n",
       "394             factor XIII concentrate (human)            Corifact   \n",
       "181  C1 Esterase Inhibitor Subcutaneous [Human]            HAEGARDA   \n",
       "102                                    baclofen              OZOBAX   \n",
       "153                      botulinum toxin type A               Botox   \n",
       "847                                   rituximab             Rituxan   \n",
       "240         coagulation factor IX (recombinant)             BeneFIX   \n",
       "\n",
       "         Date Designated                                 Orphan Designation  \\\n",
       "984  1986-01-17 00:00:00  Prevention of cystine nephrolithiasis in patie...   \n",
       "985  1986-01-17 00:00:00  Prevention of cystine nephrolithiasis in patie...   \n",
       "22   1988-01-19 00:00:00                      Treatment of Fabry's disease.   \n",
       "741  1989-10-20 00:00:00           Treatment of acute lymphocytic leukemia.   \n",
       "394  1985-01-16 00:00:00     Treatment of congenital factor XIII deficiency   \n",
       "181  1992-10-16 00:00:00  Prevention and/or treatment of acute attacks o...   \n",
       "102  1991-12-16 00:00:00  Treatment of intractable spasticity due to mul...   \n",
       "153  1991-12-06 00:00:00  Treatment of dynamic muscle contracture in ped...   \n",
       "847  1994-06-13 00:00:00         Treatment of non-Hodgkin's B-cell lymphoma   \n",
       "240  1994-10-03 00:00:00                          Treatment of hemophilia B   \n",
       "\n",
       "    Orphan Designation Status  \\\n",
       "984       Designated/Approved   \n",
       "985       Designated/Approved   \n",
       "22        Designated/Approved   \n",
       "741       Designated/Approved   \n",
       "394       Designated/Approved   \n",
       "181       Designated/Approved   \n",
       "102       Designated/Approved   \n",
       "153       Designated/Approved   \n",
       "847       Designated/Approved   \n",
       "240       Designated/Approved   \n",
       "\n",
       "                           Approved Labeled Indication  \\\n",
       "984  THIOLA EC is indicated, in combination with hi...   \n",
       "985  THIOLA is indicated, in combination with high ...   \n",
       "22   treatment of adult and pediatric patients 2 ye...   \n",
       "741  ASPARLAS is indicated as a component of a mult...   \n",
       "394  Indicated for routine prophylactic treatment a...   \n",
       "181  HAEGARDA is a plasma-derived concentrate of C1...   \n",
       "102  Treatment of spasticity resulting from multipl...   \n",
       "153  BOTOX is indicated for the treatment of upper ...   \n",
       "847  treatment of pediatric patients aged 6 months ...   \n",
       "240  Routine prophylaxis to reduce the frequency of...   \n",
       "\n",
       "    Marketing Approval Date Exclusivity End Date  \\\n",
       "984     2019-06-28 00:00:00           06/28/2026   \n",
       "985     2019-06-28 00:00:00           06/28/2026   \n",
       "22      2021-03-11 00:00:00              3/11/28   \n",
       "741     2018-12-20 00:00:00                  NaN   \n",
       "394     2013-01-24 00:00:00           01/24/2020   \n",
       "181     2020-09-24 00:00:00                  NaN   \n",
       "102     2019-09-18 00:00:00                  NaN   \n",
       "153     2019-06-20 00:00:00           06/20/2026   \n",
       "847     2021-12-02 00:00:00                  NaN   \n",
       "240     2021-10-05 00:00:00                  NaN   \n",
       "\n",
       "    Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)  \\\n",
       "984                                                NaN                                           \n",
       "985  Indicated in combination with high fluid intak...                                           \n",
       "22   treatment of pediatric patients 2 years of age...                                           \n",
       "741                                                NaN                                           \n",
       "394  Peri-operative management of surgical bleeding...                                           \n",
       "181                                                NaN                                           \n",
       "102                                                NaN                                           \n",
       "153  For the treatment of upper limb spasticity in ...                                           \n",
       "847                                                NaN                                           \n",
       "240                                                NaN                                           \n",
       "\n",
       "                                       Sponsor Company  \\\n",
       "984                          Mission Pharmacal Company   \n",
       "985                          Mission Pharmacal Company   \n",
       "22                                 Genzyme Corporation   \n",
       "741                        Servier Pharmaceuticals LLC   \n",
       "394                                    CSL Behring LLC   \n",
       "181                                    CSL Behring LLC   \n",
       "102                       Metacel Pharmaceuticals, LLC   \n",
       "153                                     Allergan, Inc.   \n",
       "847                                    Genentech, Inc.   \n",
       "240  Wyeth Pharmaceuticals LLC, a subsidiary of Pfi...   \n",
       "\n",
       "           Sponsor Address 1         Sponsor City  Sponsor State Sponsor Zip  \\\n",
       "984          P.O. Box 786099          San Antonio          Texas       78278   \n",
       "985          P.O. Box 786099          San Antonio          Texas       78278   \n",
       "22          50 Binney Street            Cambridge  Massachusetts        2142   \n",
       "741       200 Pier Four Blvd               Boston  Massachusetts        2210   \n",
       "394          1020 First Ave.      King of Prussia   Pennsylvania       19406   \n",
       "181        1020 First Avenue      King of Prussia   Pennsylvania       19406   \n",
       "102  244 E Washington Street               Athens        Georgia       30601   \n",
       "153        2525 Dupont Drive               Irvine     California       92623   \n",
       "847        1 DNA Way, MS 242  South San Francisco     California       94080   \n",
       "240   235 E. 42nd St 219/9/1             New York       New York       10017   \n",
       "\n",
       "    Sponsor Country  Time_diff  \n",
       "984   United States      12215  \n",
       "985   United States      12215  \n",
       "22    United States      12105  \n",
       "741   United States      10653  \n",
       "394   United States      10235  \n",
       "181   United States      10205  \n",
       "102   United States      10138  \n",
       "153   United States      10058  \n",
       "847   United States      10034  \n",
       "240   United States       9864  "
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Sort the data according to column Time_diff in descending order\n",
    "df_new = df.sort_values(['Time_diff'], ascending = False, axis = 0, inplace = True)\n",
    "df_new_top10 = df.head(10)\n",
    "df_new_top10"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "e12922bd",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Generic Name</th>\n",
       "      <th>Time_diff</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>984</th>\n",
       "      <td>Tiopronin</td>\n",
       "      <td>12215</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>985</th>\n",
       "      <td>Tiopronin</td>\n",
       "      <td>12215</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>agalsidase beta</td>\n",
       "      <td>12105</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>741</th>\n",
       "      <td>Pegaspargase</td>\n",
       "      <td>10653</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>394</th>\n",
       "      <td>factor XIII concentrate (human)</td>\n",
       "      <td>10235</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>181</th>\n",
       "      <td>C1 Esterase Inhibitor Subcutaneous [Human]</td>\n",
       "      <td>10205</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>102</th>\n",
       "      <td>baclofen</td>\n",
       "      <td>10138</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>153</th>\n",
       "      <td>botulinum toxin type A</td>\n",
       "      <td>10058</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>847</th>\n",
       "      <td>rituximab</td>\n",
       "      <td>10034</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>240</th>\n",
       "      <td>coagulation factor IX (recombinant)</td>\n",
       "      <td>9864</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                   Generic Name  Time_diff\n",
       "984                                   Tiopronin      12215\n",
       "985                                   Tiopronin      12215\n",
       "22                              agalsidase beta      12105\n",
       "741                                Pegaspargase      10653\n",
       "394             factor XIII concentrate (human)      10235\n",
       "181  C1 Esterase Inhibitor Subcutaneous [Human]      10205\n",
       "102                                    baclofen      10138\n",
       "153                      botulinum toxin type A      10058\n",
       "847                                   rituximab      10034\n",
       "240         coagulation factor IX (recombinant)       9864"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Create another dataframe with only Generic Name and Time_diff columns\n",
    "df_new_top10_1 = df_new_top10[['Generic Name', 'Time_diff']]\n",
    "df_new_top10_1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "d7f76ca8",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Time_diff</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Generic Name</th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>Tiopronin</th>\n",
       "      <td>12215</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Tiopronin</th>\n",
       "      <td>12215</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>agalsidase beta</th>\n",
       "      <td>12105</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Pegaspargase</th>\n",
       "      <td>10653</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>factor XIII concentrate (human)</th>\n",
       "      <td>10235</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>C1 Esterase Inhibitor Subcutaneous [Human]</th>\n",
       "      <td>10205</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>baclofen</th>\n",
       "      <td>10138</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>botulinum toxin type A</th>\n",
       "      <td>10058</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>rituximab</th>\n",
       "      <td>10034</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>coagulation factor IX (recombinant)</th>\n",
       "      <td>9864</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                            Time_diff\n",
       "Generic Name                                         \n",
       "Tiopronin                                       12215\n",
       "Tiopronin                                       12215\n",
       "agalsidase beta                                 12105\n",
       "Pegaspargase                                    10653\n",
       "factor XIII concentrate (human)                 10235\n",
       "C1 Esterase Inhibitor Subcutaneous [Human]      10205\n",
       "baclofen                                        10138\n",
       "botulinum toxin type A                          10058\n",
       "rituximab                                       10034\n",
       "coagulation factor IX (recombinant)              9864"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Use Generic name column as the index instead\n",
    "df_new_top10_1.set_index('Generic Name', inplace = True)\n",
    "df_new_top10_1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "b4ea2258",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Text(0.5, 1.0, 'Top 10 rare disease drugs with the longest time required to reach marketing approval')"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1080x1080 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Plot horizontal bar graph of the top 10 rare disease drugs with longest time taken to reach marketing approval\n",
    "df_new_top10_1.plot(kind = 'barh', figsize = (15, 15))\n",
    "plt.xlabel('Days')\n",
    "plt.title('Top 10 rare disease drugs with the longest time required to reach marketing approval')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "d60f9bc2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Generic Name</th>\n",
       "      <th>Trade Name</th>\n",
       "      <th>Date Designated</th>\n",
       "      <th>Marketing Approval Date</th>\n",
       "      <th>Time_diff</th>\n",
       "      <th>Approved Labeled Indication</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>984</th>\n",
       "      <td>Tiopronin</td>\n",
       "      <td>Thiola</td>\n",
       "      <td>1986-01-17 00:00:00</td>\n",
       "      <td>2019-06-28 00:00:00</td>\n",
       "      <td>12215</td>\n",
       "      <td>THIOLA EC is indicated, in combination with hi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>985</th>\n",
       "      <td>Tiopronin</td>\n",
       "      <td>Thiola</td>\n",
       "      <td>1986-01-17 00:00:00</td>\n",
       "      <td>2019-06-28 00:00:00</td>\n",
       "      <td>12215</td>\n",
       "      <td>THIOLA is indicated, in combination with high ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>agalsidase beta</td>\n",
       "      <td>Fabrazyme</td>\n",
       "      <td>1988-01-19 00:00:00</td>\n",
       "      <td>2021-03-11 00:00:00</td>\n",
       "      <td>12105</td>\n",
       "      <td>treatment of adult and pediatric patients 2 ye...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>741</th>\n",
       "      <td>Pegaspargase</td>\n",
       "      <td>Oncaspar; Asparlas</td>\n",
       "      <td>1989-10-20 00:00:00</td>\n",
       "      <td>2018-12-20 00:00:00</td>\n",
       "      <td>10653</td>\n",
       "      <td>ASPARLAS is indicated as a component of a mult...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>394</th>\n",
       "      <td>factor XIII concentrate (human)</td>\n",
       "      <td>Corifact</td>\n",
       "      <td>1985-01-16 00:00:00</td>\n",
       "      <td>2013-01-24 00:00:00</td>\n",
       "      <td>10235</td>\n",
       "      <td>Indicated for routine prophylactic treatment a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>181</th>\n",
       "      <td>C1 Esterase Inhibitor Subcutaneous [Human]</td>\n",
       "      <td>HAEGARDA</td>\n",
       "      <td>1992-10-16 00:00:00</td>\n",
       "      <td>2020-09-24 00:00:00</td>\n",
       "      <td>10205</td>\n",
       "      <td>HAEGARDA is a plasma-derived concentrate of C1...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>102</th>\n",
       "      <td>baclofen</td>\n",
       "      <td>OZOBAX</td>\n",
       "      <td>1991-12-16 00:00:00</td>\n",
       "      <td>2019-09-18 00:00:00</td>\n",
       "      <td>10138</td>\n",
       "      <td>Treatment of spasticity resulting from multipl...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>153</th>\n",
       "      <td>botulinum toxin type A</td>\n",
       "      <td>Botox</td>\n",
       "      <td>1991-12-06 00:00:00</td>\n",
       "      <td>2019-06-20 00:00:00</td>\n",
       "      <td>10058</td>\n",
       "      <td>BOTOX is indicated for the treatment of upper ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>847</th>\n",
       "      <td>rituximab</td>\n",
       "      <td>Rituxan</td>\n",
       "      <td>1994-06-13 00:00:00</td>\n",
       "      <td>2021-12-02 00:00:00</td>\n",
       "      <td>10034</td>\n",
       "      <td>treatment of pediatric patients aged 6 months ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>240</th>\n",
       "      <td>coagulation factor IX (recombinant)</td>\n",
       "      <td>BeneFIX</td>\n",
       "      <td>1994-10-03 00:00:00</td>\n",
       "      <td>2021-10-05 00:00:00</td>\n",
       "      <td>9864</td>\n",
       "      <td>Routine prophylaxis to reduce the frequency of...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                   Generic Name          Trade Name  \\\n",
       "984                                   Tiopronin              Thiola   \n",
       "985                                   Tiopronin              Thiola   \n",
       "22                              agalsidase beta           Fabrazyme   \n",
       "741                                Pegaspargase  Oncaspar; Asparlas   \n",
       "394             factor XIII concentrate (human)            Corifact   \n",
       "181  C1 Esterase Inhibitor Subcutaneous [Human]            HAEGARDA   \n",
       "102                                    baclofen              OZOBAX   \n",
       "153                      botulinum toxin type A               Botox   \n",
       "847                                   rituximab             Rituxan   \n",
       "240         coagulation factor IX (recombinant)             BeneFIX   \n",
       "\n",
       "         Date Designated Marketing Approval Date  Time_diff  \\\n",
       "984  1986-01-17 00:00:00     2019-06-28 00:00:00      12215   \n",
       "985  1986-01-17 00:00:00     2019-06-28 00:00:00      12215   \n",
       "22   1988-01-19 00:00:00     2021-03-11 00:00:00      12105   \n",
       "741  1989-10-20 00:00:00     2018-12-20 00:00:00      10653   \n",
       "394  1985-01-16 00:00:00     2013-01-24 00:00:00      10235   \n",
       "181  1992-10-16 00:00:00     2020-09-24 00:00:00      10205   \n",
       "102  1991-12-16 00:00:00     2019-09-18 00:00:00      10138   \n",
       "153  1991-12-06 00:00:00     2019-06-20 00:00:00      10058   \n",
       "847  1994-06-13 00:00:00     2021-12-02 00:00:00      10034   \n",
       "240  1994-10-03 00:00:00     2021-10-05 00:00:00       9864   \n",
       "\n",
       "                           Approved Labeled Indication  \n",
       "984  THIOLA EC is indicated, in combination with hi...  \n",
       "985  THIOLA is indicated, in combination with high ...  \n",
       "22   treatment of adult and pediatric patients 2 ye...  \n",
       "741  ASPARLAS is indicated as a component of a mult...  \n",
       "394  Indicated for routine prophylactic treatment a...  \n",
       "181  HAEGARDA is a plasma-derived concentrate of C1...  \n",
       "102  Treatment of spasticity resulting from multipl...  \n",
       "153  BOTOX is indicated for the treatment of upper ...  \n",
       "847  treatment of pediatric patients aged 6 months ...  \n",
       "240  Routine prophylaxis to reduce the frequency of...  "
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#To add more columns to df_new_top10_1 dataframe to show more information\n",
    "df_new_top10_2 = df_new_top10[['Generic Name', 'Trade Name', 'Date Designated', 'Marketing Approval Date', 'Time_diff', 'Approved Labeled Indication']]\n",
    "df_new_top10_2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "e508c6d4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['THIOLA EC is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone.',\n",
       "       'THIOLA is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone.',\n",
       "       'treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease',\n",
       "       'ASPARLAS is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.',\n",
       "       'Indicated for routine prophylactic treatment and peri-operative management of surgical bleeding in adult and pediatric patients with congenital FXIII deficiency.',\n",
       "       'HAEGARDA is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) (C1-INH) indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older',\n",
       "       'Treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. OZOBAX may also be of some value in patients with spinal cord injuries and other spinal cord diseases.',\n",
       "       'BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age.',\n",
       "       'treatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy',\n",
       "       'Routine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hemophilia B (congenital factor IX deficiency or Christmas disease)'],\n",
       "      dtype=object)"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Showing detailed approved labeled indications for the top 10 rare disease drugs that took the longest time to reach markets\n",
    "df_new_top10_2['Approved Labeled Indication'].unique()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "63b385ca",
   "metadata": {},
   "source": [
    "The horizontal bar graph above displayed the top ten rare disease drugs with the longest time taken to reach the market. The data for Tiopronin appeared to be duplicates, but note that the two were formulated differently as one of them was the enteric-coated (EC) version (marketed as delayed-release tablets under the actual trade name of \"Thiola EC\", but recorded in the dataset as \"Thiola\" only), while the other one was the immediate-release form (Thiola)."
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
